BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60:861-868. [PMID: 20966025 DOI: 10.1136/gut.2010.226092] [Cited by in Crossref: 473] [Cited by in F6Publishing: 481] [Article Influence: 39.4] [Reference Citation Analysis]
Number Citing Articles
1 Nones K, Waddell N, Song S, Patch AM, Miller D, Johns A, Wu J, Kassahn KS, Wood D, Bailey P. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 2014;135:1110-1118. [PMID: 24500968 DOI: 10.1002/ijc.28765] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 16.1] [Reference Citation Analysis]
2 Iida-Norita R, Kawamura M, Suzuki Y, Hamada S, Masamune A, Furukawa T, Sato Y. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma. Cancer Sci 2019;110:2296-308. [PMID: 31074083 DOI: 10.1111/cas.14041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Arcucci A, Ruocco MR, Granato G, Sacco AM, Montagnani S. Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts. Biomed Res Int 2016;2016:4502846. [PMID: 27595103 DOI: 10.1155/2016/4502846] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
4 Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol 2018; 24(33): 3709-3723 [PMID: 30197477 DOI: 10.3748/wjg.v24.i33.3709] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
5 Harris NLE, Vennin C, Conway JRW, Vine KL, Pinese M, Cowley MJ, Shearer RF, Lucas MC, Herrmann D, Allam AH, Pajic M, Morton JP;  Australian Pancreatic Cancer Genome Initiative; Biankin AV, Ranson M, Timpson P, Saunders DN. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene. 2017;36:4288-4298. [PMID: 28346421 DOI: 10.1038/onc.2017.63] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
6 Ozmen F, Şahin TT, Ozmen MM. Current adjuvant therapeutic approaches for pancreatic cancer. Adv Ther 2015;32:42-56. [PMID: 25595483 DOI: 10.1007/s12325-015-0177-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
7 Timaner M, Shaked Y. Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer. J Pathol 2020;250:123-5. [DOI: 10.1002/path.5355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Singh AP, Arora S, Bhardwaj A, Srivastava SK, Kadakia MP, Wang B, Grizzle WE, Owen LB, Singh S. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions. J Biol Chem 2012;287:39115-24. [PMID: 22995914 DOI: 10.1074/jbc.M112.409581] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 8.2] [Reference Citation Analysis]
9 Damhofer H, Medema JP, Veenstra VL, Badea L, Popescu I, Roelink H, Bijlsma MF. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. Mol Oncol. 2013;7:1031-1042. [PMID: 23998958 DOI: 10.1016/j.molonc.2013.08.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
10 Tingle SJ, Moir JA, White SA. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol 2015; 6(4): 235-242 [PMID: 26600982 DOI: 10.4291/wjgp.v6.i4.235] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci. 2013;14:19731-19762. [PMID: 24084722 DOI: 10.3390/ijms141019731] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
12 Zambirinis CP, Miller G. Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. Trends Mol Med 2017;23:465-81. [PMID: 28400243 DOI: 10.1016/j.molmed.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
13 Hompland T, Ellingsen C, Galappathi K, Rofstad EK. Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI. Acta Oncol 2014;53:6-15. [PMID: 23445339 DOI: 10.3109/0284186X.2013.773073] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
14 Wu L, Lv P, Zhang H, Fu C, Yao X, Wang C, Zeng M, Li Y, Wang X. Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model. Magnetic Resonance Imaging 2015;33:737-60. [DOI: 10.1016/j.mri.2014.08.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
15 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
16 Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, Wouters A, Lardon F, Roeyen G, Verhoeven Y, Janssens A, Vandamme T, van Dam P, Peeters M, Prenen H. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers (Basel) 2021;13:987. [PMID: 33673405 DOI: 10.3390/cancers13050987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
18 Langer EM, Allen-Petersen BL, King SM, Kendsersky ND, Turnidge MA, Kuziel GM, Riggers R, Samatham R, Amery TS, Jacques SL, Sheppard BC, Korkola JE, Muschler JL, Thibault G, Chang YH, Gray JW, Presnell SC, Nguyen DG, Sears RC. Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting. Cell Rep 2019;26:608-623.e6. [PMID: 30650355 DOI: 10.1016/j.celrep.2018.12.090] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 32.5] [Reference Citation Analysis]
19 Gharibi A, Adamian Y, Kelber JA. Cellular and molecular aspects of pancreatic cancer. Acta Histochem 2016;118:305-16. [PMID: 26868366 DOI: 10.1016/j.acthis.2016.01.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
20 Liu D, Steins A, Klaassen R, van der Zalm AP, Bennink RJ, van Tienhoven G, Besselink MG, Bijlsma MF, van Laarhoven HWM. Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. Biomedicines 2020;8:E444. [PMID: 33105540 DOI: 10.3390/biomedicines8110444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cho IK, Kim H, Lee JC, Lee J, Kim J, Ahn S, Park H, Hwang JH. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Gut Liver 2020;14:521-8. [PMID: 31615191 DOI: 10.5009/gnl19180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J 2019;286:3510-39. [PMID: 31330086 DOI: 10.1111/febs.15011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
23 Matkar PN, Singh KK, Rudenko D, Kim YJ, Kuliszewski MA, Prud'homme GJ, Hedley DW, Leong-Poi H. Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:69489-506. [PMID: 27542226 DOI: 10.18632/oncotarget.11060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
24 Murakawa M, Aoyama T, Miyagi Y, Kobayashi S, Ueno M, Morimoto M, Numata M, Yamamoto N, Tamagawa H, Yukawa N, Rino Y, Masuda M, Morinaga S. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. J Cancer 2019;10:627-33. [PMID: 30719160 DOI: 10.7150/jca.28660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
25 Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, Liu J, Xiang J, Liang D, Hu Q, Liu L, Liu C, Luo G, Ni Q, Xu J, Yu X. Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin 2016;48:969-79. [DOI: 10.1093/abbs/gmw097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
26 Opitz FV, Haeberle L, Daum A, Esposito I. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. Cancers 2021;13:6188. [DOI: 10.3390/cancers13246188] [Reference Citation Analysis]
27 Ding J, Li H, Liu Y, Xie Y, Yu J, Sun H, Xiao D, Zhou Y, Bao L, Wang H, Gao C. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:698302. [PMID: 34804914 DOI: 10.3389/fonc.2021.698302] [Reference Citation Analysis]
28 Shi K, Damhofer H, Daalhuisen J, Ten Brink M, Richel DJ, Spek CA. Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. Mol Med 2017;23:13-23. [PMID: 28182192 DOI: 10.2119/molmed.2016.00214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
29 Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol. 2013;10:1312-1323. [PMID: 23807417 DOI: 10.4161/rna.25274] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
30 Yako YY, Kruger D, Smith M, Brand M. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS One. 2016;11:e0154016. [PMID: 27170998 DOI: 10.1371/journal.pone.0154016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
31 Fuchigami H, Manabe S, Yasunaga M, Matsumura Y. Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Sci Rep 2018;8:14211. [PMID: 30242282 DOI: 10.1038/s41598-018-32601-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
32 Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine 2019;20:102027. [PMID: 31170509 DOI: 10.1016/j.nano.2019.102027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
33 Sato D, Tsuchikawa T, Mitsuhashi T, Hatanaka Y, Marukawa K, Morooka A, Nakamura T, Shichinohe T, Matsuno Y, Hirano S. Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma. PLoS One. 2016;11:e0152523. [PMID: 27023252 DOI: 10.1371/journal.pone.0152523] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
34 Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol 2021;14:101056. [PMID: 33684837 DOI: 10.1016/j.tranon.2021.101056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
36 Yuan Y, Jiang JY, Wang JM, Sun J, Li C, Liu BQ, Yan J, Meng XN, Wang HQ. BAG3-positive pancreatic stellate cells promote migration and invasion of pancreatic ductal adenocarcinoma. J Cell Mol Med 2019;23:5006-16. [PMID: 31119886 DOI: 10.1111/jcmm.14352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
38 Masamune A, Shimosegawa T. Pancreatic stellate cells: A dynamic player of the intercellular communication in pancreatic cancer. Clin Res Hepatol Gastroenterol 2015;39 Suppl 1:S98-103. [PMID: 26189983 DOI: 10.1016/j.clinre.2015.05.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
39 Fang Y, Saiyin H, Zhao X, Wu Y, Han X, Lou W. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. Pancreas 2016;45:671-8. [PMID: 26495785 DOI: 10.1097/MPA.0000000000000520] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Timaner M, Letko-Khait N, Kotsofruk R, Benguigui M, Beyar-Katz O, Rachman-Tzemah C, Raviv Z, Bronshtein T, Machluf M, Shaked Y. Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells. Cancer Res 2018;78:1253-65. [PMID: 29301792 DOI: 10.1158/0008-5472.CAN-17-1547] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
41 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
42 Chen Y, Ren W, Zheng D, Zhong J, Liu X, Yue Q, Liu M, Xiao Y, Chen W, Chan Q. Diffusion kurtosis imaging predicts neoadjuvant chemotherapy responses within 4 days in advanced nasopharyngeal carcinoma patients. J Magn Reson Imaging. 2015;42:1354-1361. [PMID: 25873208 DOI: 10.1002/jmri.24910] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
43 Musa M. Single-cell analysis on stromal fibroblasts in the microenvironment of solid tumours. Adv Med Sci 2020;65:163-9. [PMID: 31972467 DOI: 10.1016/j.advms.2019.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
45 Yoshida M, Miyasaka Y, Ohuchida K, Okumura T, Zheng B, Torata N, Fujita H, Nabae T, Manabe T, Shimamoto M, Ohtsuka T, Mizumoto K, Nakamura M. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. Cancer Sci 2016;107:1443-52. [PMID: 27487486 DOI: 10.1111/cas.13024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
46 Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 2018;115:E3769-78. [PMID: 29615514 DOI: 10.1073/pnas.1722434115] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 12.5] [Reference Citation Analysis]
47 Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezène P, Dusetti NJ, Loncle C, Calvo E, Turrini O. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2013;110:3919-3924. [PMID: 23407165 DOI: 10.1073/pnas.1219555110] [Cited by in Crossref: 222] [Cited by in F6Publishing: 208] [Article Influence: 24.7] [Reference Citation Analysis]
48 Mathew E, Brannon AL, Del Vecchio A, Garcia PE, Penny MK, Kane KT, Vinta A, Buckanovich RJ, di Magliano MP. Mesenchymal Stem Cells Promote Pancreatic Tumor Growth by Inducing Alternative Polarization of Macrophages. Neoplasia. 2016;18:142-151. [PMID: 26992915 DOI: 10.1016/j.neo.2016.01.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
49 Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368-402. [PMID: 24183261 DOI: 10.1016/j.disamonth.2013.08.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 8.4] [Reference Citation Analysis]
50 Fitzgerald AA, Li E, Weiner LM. 3D Culture Systems for Exploring Cancer Immunology. Cancers (Basel) 2020;13:E56. [PMID: 33379189 DOI: 10.3390/cancers13010056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Steele CW, Jamieson NB, Evans TR, McKay CJ, Sansom OJ, Morton JP, Carter CR. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013;108:997-1003. [PMID: 23385734 DOI: 10.1038/bjc.2013.24] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
52 Toste PA, Nguyen AH, Kadera BE, Duong M, Wu N, Gawlas I, Tran LM, Bikhchandani M, Li L, Patel SG, Dawson DW, Donahue TR. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK. Mol Cancer Res 2016;14:437-47. [PMID: 26979711 DOI: 10.1158/1541-7786.MCR-15-0348] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
53 Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016; 22(2): 776-789 [PMID: 26811624 DOI: 10.3748/wjg.v22.i2.776] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
54 Niyaz M, Khan MS, Mudassar S. Hedgehog Signaling: An Achilles' Heel in Cancer. Transl Oncol 2019;12:1334-44. [PMID: 31352196 DOI: 10.1016/j.tranon.2019.07.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
55 Wang K, He H. Pancreatic Tumor Microenvironment. Adv Exp Med Biol 2020;1296:243-57. [PMID: 34185297 DOI: 10.1007/978-3-030-59038-3_15] [Reference Citation Analysis]
56 LeBleu VS. Imaging the Tumor Microenvironment. Cancer J 2015;21:174-8. [PMID: 26049696 DOI: 10.1097/PPO.0000000000000118] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
57 Thakur C, Chen F. Connections between metabolism and epigenetics in cancers. Semin Cancer Biol 2019;57:52-8. [PMID: 31185282 DOI: 10.1016/j.semcancer.2019.06.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
58 Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials 2015;53:731-43. [PMID: 25890768 DOI: 10.1016/j.biomaterials.2015.02.082] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
59 Khan MA, Srivastava SK, Bhardwaj A, Singh S, Arora S, Zubair H, Carter JE, Singh AP. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Oncotarget 2015;6:39140-50. [PMID: 25970774 DOI: 10.18632/oncotarget.3784] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
60 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
61 Xia G, Zhang H, Cheng R, Wang H, Song Z, Deng L, Huang X, Santos HA, Cui W. Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence. Adv Healthcare Mater 2018;7:1800593. [DOI: 10.1002/adhm.201800593] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
62 Torres MP, Chakraborty S, Souchek J, Batra SK. Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des. 2012;18:2472-2481. [PMID: 22372499 DOI: 10.2174/13816128112092472] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
63 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
64 Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol 2016;10:301-16. [PMID: 26560854 DOI: 10.1586/17474124.2016.1117386] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 9.4] [Reference Citation Analysis]
65 Bhaw-Luximon A, Jhurry D. New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: Selective stroma depletion combined with nano drug delivery. Cancer Lett. 2015;369:266-273. [PMID: 26415628 DOI: 10.1016/j.canlet.2015.09.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
66 Pandey V, Storz P. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther 2019;19:473-82. [PMID: 31148495 DOI: 10.1080/14737140.2019.1622417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
67 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
68 Lee JJ, Huang J, England CG, McNally LR, Frieboes HB. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS Comput Biol 2013;9:e1003231. [PMID: 24068909 DOI: 10.1371/journal.pcbi.1003231] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
69 Zhang Z, Qin Y, Ji S, Xu W, Liu M, Hu Q, Ye Z, Fan G, Yu X, Liu W, Xu X. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Acta Biochim Biophys Sin (Shanghai) 2021;53:997-1008. [PMID: 34117747 DOI: 10.1093/abbs/gmab074] [Reference Citation Analysis]
70 Cao Y, Aryal M, Li P, Lee C, Schipper M, Hawkins PG, Chapman C, Owen D, Dragovic AF, Swiecicki P, Casper K, Worden F, Lawrence TS, Eisbruch A, Mierzwa M. Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16- High Risk Head and Neck Cancer. Front Oncol 2019;9:1118. [PMID: 31799173 DOI: 10.3389/fonc.2019.01118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
71 Wang WQ, Liu L, Xu JZ, Yu XJ. Reflections on depletion of tumor stroma in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2019;1871:267-72. [PMID: 30738097 DOI: 10.1016/j.bbcan.2019.01.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
72 Xu Y, Karmakar A, Heberlein WE, Mustafa T, Biris AR, Biris AS. Multifunctional magnetic nanoparticles for synergistic enhancement of cancer treatment by combinatorial radio frequency thermolysis and drug delivery. Adv Healthc Mater 2012;1:493-501. [PMID: 23184783 DOI: 10.1002/adhm.201200079] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
73 Hamdy A, Ichikawa Y, Toyomasu Y, Nagata M, Nagasawa N, Nomoto Y, Sami H, Sakuma H. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience. Radiology. 2019;292:628-635. [PMID: 31287389 DOI: 10.1148/radiol.2019182561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
74 Meng H, Nel AE. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Adv Drug Deliv Rev 2018;130:50-7. [PMID: 29958925 DOI: 10.1016/j.addr.2018.06.014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
75 Miao L, Huang L. Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res 2015;166:193-226. [PMID: 25895870 DOI: 10.1007/978-3-319-16555-4_9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis]
76 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
77 Hu H, Jiao F, Han T, Wang LW. Functional significance of macrophages in pancreatic cancer biology. Tumour Biol. 2015;36:9119-9126. [PMID: 26411672 DOI: 10.1007/s13277-015-4127-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
78 Alam MS, Gaida MM, Bergmann F, Lasitschka F, Giese T, Giese NA, Hackert T, Hinz U, Hussain SP, Kozlov SV, Ashwell JD. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Nat Med. 2015;21:1337-1343. [PMID: 26479921 DOI: 10.1038/nm.3957] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
79 Monkman JH, Thompson EW, Nagaraj SH. Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. Cancers (Basel) 2019;11:E1745. [PMID: 31703358 DOI: 10.3390/cancers11111745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Wang J, Lee JS, Kim D, Zhu L. Exploration of Zinc Oxide Nanoparticles as a Multitarget and Multifunctional Anticancer Nanomedicine. ACS Appl Mater Interfaces 2017;9:39971-84. [DOI: 10.1021/acsami.7b11219] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 12.6] [Reference Citation Analysis]
81 Duconseil P, Gilabert M, Gayet O, Loncle C, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Iovanna J, Dusetti N. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Am J Pathol 2015;185:1022-32. [PMID: 25765988 DOI: 10.1016/j.ajpath.2014.11.029] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
82 Griesmann H, Drexel C, Milosevic N, Sipos B, Rosendahl J, Gress TM, Michl P. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Gut. 2017;66:1278-1285. [PMID: 27013602 DOI: 10.1136/gutjnl-2015-310049] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
83 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
84 Li Y, Zhao Z, Liu H, Fetse JP, Jain A, Lin CY, Cheng K. Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. ACS Appl Mater Interfaces 2019;11:45390-403. [PMID: 31769963 DOI: 10.1021/acsami.9b15116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
85 Iovanna JL, Marks DL, Fernandez-Zapico ME, Urrutia R. Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer. Am J Pathol 2013;182:1078-86. [PMID: 23375449 DOI: 10.1016/j.ajpath.2012.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
86 di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144:1220-1229. [PMID: 23622131 DOI: 10.1053/j.gastro.2013.01.071] [Cited by in Crossref: 230] [Cited by in F6Publishing: 218] [Article Influence: 25.6] [Reference Citation Analysis]
87 Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, Oupicky D. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Pharmacol Ther. 2017;179:158-170. [PMID: 28549596 DOI: 10.1016/j.pharmthera.2017.05.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 12.6] [Reference Citation Analysis]
88 Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, Liu J, Xiang J, Liang D, Hu Q, Ni Q, Xu J, Yu X. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Biochim Biophys Acta. 2016;1866:177-188. [PMID: 27600832 DOI: 10.1016/j.bbcan.2016.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
89 Mukherjee L, Bui HD, Keikhosravi A, Loeffler A, Eliceiri K. Super-resolution recurrent convolutional neural networks for learning with multi-resolution whole slide images. J Biomed Opt 2019;24:1-15. [PMID: 31837128 DOI: 10.1117/1.JBO.24.12.126003] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
90 Folch-Puy E. REG3β contributes to the immunosuppressive microenvironment of pancreatic cancer. Oncoimmunology 2013;2:e26404. [PMID: 24353919 DOI: 10.4161/onci.26404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
91 Sommariva M, Gagliano N. E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor during EMT. Cells 2020;9:E1040. [PMID: 32331358 DOI: 10.3390/cells9041040] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
92 Daenen LG, Houthuijzen JM, Cirkel GA, Roodhart JM, Shaked Y, Voest EE. Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies. Oncogene 2014;33:1341-7. [PMID: 23524584 DOI: 10.1038/onc.2013.94] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
93 Anbil S, Pigula M, Huang HC, Mallidi S, Broekgaarden M, Baglo Y, De Silva P, Simeone DM, Mino-Kenudson M, Maytin EV, Rizvi I, Hasan T. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Mol Cancer Ther 2020;19:1308-19. [PMID: 32220968 DOI: 10.1158/1535-7163.MCT-19-0791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
94 Chakedis J, French R, Babicky M, Jaquish D, Howard H, Mose E, Lam R, Holman P, Miyamoto J, Walterscheid Z, Lowy AM. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene 2016;35:3249-59. [PMID: 26477314 DOI: 10.1038/onc.2015.384] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
95 Luo D, Carter KA, Molins EAG, Straubinger NL, Geng J, Shao S, Jusko WJ, Straubinger RM, Lovell JF. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. J Control Release 2019;297:39-47. [PMID: 30684512 DOI: 10.1016/j.jconrel.2019.01.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
96 Saison-Ridinger M, DelGiorno KE, Zhang T, Kraus A, French R, Jaquish D, Tsui C, Erikson G, Spike BT, Shokhirev MN, Liddle C, Yu RT, Downes M, Evans RM, Saghatelian A, Lowy AM, Wahl GM. Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. PLoS One 2017;12:e0189051. [PMID: 29211796 DOI: 10.1371/journal.pone.0189051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
97 Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 2015;6:15788-801. [PMID: 26158861 DOI: 10.18632/oncotarget.3819] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
98 Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews 2020;100:1707-51. [DOI: 10.1152/physrev.00042.2019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
99 Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, Witkiewicz AK. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep 2014;9:2233-49. [PMID: 25497091 DOI: 10.1016/j.celrep.2014.11.025] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 13.6] [Reference Citation Analysis]
100 Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, Trevino JG, Bentrem DJ, Munshi HG. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel) 2021;13:440. [PMID: 33503832 DOI: 10.3390/cancers13030440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Coetzee A, Grose R, Kocher H. Pancreatic Cancer Organotypic Models. Curr Top Microbiol Immunol 2021;430:183-98. [PMID: 30790075 DOI: 10.1007/82_2019_155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
102 Lennon S, Oweida A, Milner D, Phan AV, Bhatia S, Van Court B, Darragh L, Mueller AC, Raben D, Martínez-Torrecuadrada JL, Pitts TM, Somerset H, Jordan KR, Hansen KC, Williams J, Messersmith WA, Schulick RD, Owens P, Goodman KA, Karam SD. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clin Cancer Res 2019;25:3352-65. [PMID: 30944125 DOI: 10.1158/1078-0432.CCR-18-2811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 van Roey R, Brabletz T, Stemmler MP, Armstark I. Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:753456. [PMID: 34888306 DOI: 10.3389/fcell.2021.753456] [Reference Citation Analysis]
104 Raj D, Yang MH, Rodgers D, Hampton EN, Begum J, Mustafa A, Lorizio D, Garces I, Propper D, Kench JG, Kocher HM, Young TS, Aicher A, Heeschen C. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2019;68:1052-1064. [PMID: 30121627 DOI: 10.1136/gutjnl-2018-316595] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 13.3] [Reference Citation Analysis]
105 Watanabe K, Shiga K, Maeda A, Harata S, Yanagita T, Suzuki T, Ushigome H, Maeda Y, Hirokawa T, Ogawa R, Hara M, Takahashi H, Matsuo Y, Mitsui A, Kimura M, Takiguchi S. Chitinase 3-like 1 secreted from cancer-associated fibroblasts promotes tumor angiogenesis via interleukin-8 secretion in colorectal cancer. Int J Oncol 2022;60:3. [PMID: 34913066 DOI: 10.3892/ijo.2021.5293] [Reference Citation Analysis]
106 Hacking SM, Chakraborty B, Nasim R, Vitkovski T, Thomas R. A Holistic Appraisal of Stromal Differentiation in Colorectal Cancer: Biology, Histopathology, Computation, and Genomics. Pathol Res Pract 2021;220:153378. [PMID: 33690050 DOI: 10.1016/j.prp.2021.153378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
107 Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016; 22(9): 2678-2700 [PMID: 26973408 DOI: 10.3748/wjg.v22.i9.2678] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
108 Amrutkar M, Larsen EK, Aasrum M, Finstadsveen AV, Andresen PA, Verbeke CS, Gladhaug IP. Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor. Cells 2020;9:E227. [PMID: 31963309 DOI: 10.3390/cells9010227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, Giri B, Ferrantella A, Dudeja V, Saluja A, Banerjee S. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest 2020;130:451-65. [PMID: 31613799 DOI: 10.1172/JCI127515] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 19.5] [Reference Citation Analysis]
110 Deharvengt S, Marmarelis M, Korc M. Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. PLoS One 2012;7:e39684. [PMID: 22761868 DOI: 10.1371/journal.pone.0039684] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
111 Ma J, Weng L, Jia Y, Liu B, Wu S, Xue L, Yin X, Mao A, Wang Z, Shang M. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation. J Cell Mol Med 2020;24:2917-30. [PMID: 31989778 DOI: 10.1111/jcmm.14896] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
112 Hernandez-Unzueta I, Benedicto A, Romayor I, Herrero A, Sanz E, Arteta B, Olaso E, Márquez J. Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance. Pancreas 2019;48:555-67. [PMID: 30946238 DOI: 10.1097/MPA.0000000000001277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
113 Wang LM, Silva MA, D'Costa Z, Bockelmann R, Soonawalla Z, Liu S, O'Neill E, Mukherjee S, McKenna WG, Muschel R, Fokas E. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:4183-94. [PMID: 26716653 DOI: 10.18632/oncotarget.6770] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
114 McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 2014;5:2. [PMID: 24478715 DOI: 10.3389/fphys.2014.00002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
115 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med. 2012;60:643-663. [PMID: 22406516 DOI: 10.231/jim.0b013e31824a4d79] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Ferrara B, Pignatelli C, Cossutta M, Citro A, Courty J, Piemonti L. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers (Basel) 2021;13:4442. [PMID: 34503252 DOI: 10.3390/cancers13174442] [Reference Citation Analysis]
117 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
118 Le QV, Suh J, Oh YK. Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy. AAPS J 2019;21:64. [PMID: 31102154 DOI: 10.1208/s12248-019-0333-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
119 Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 2016;150:48-63. [PMID: 26385075 DOI: 10.1053/j.gastro.2015.08.056] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
120 Murphy KJ, Chambers CR, Herrmann D, Timpson P, Pereira BA. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Cancers (Basel) 2021;13:3481. [PMID: 34298706 DOI: 10.3390/cancers13143481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Wei Y, Song S, Duan N, Wang F, Wang Y, Yang Y, Peng C, Li J, Nie D, Zhang X, Guo S, Zhu C, Yu M, Gan Y. MT1-MMP-Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy. Adv Sci (Weinh) 2020;7:1902746. [PMID: 32995113 DOI: 10.1002/advs.201902746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
122 Myint ZW, Goel G. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol. 2017;10:86. [PMID: 28434400 DOI: 10.1186/s13045-017-0454-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
123 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
124 Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut 2019;68:159-71. [PMID: 30177543 DOI: 10.1136/gutjnl-2018-316451] [Cited by in Crossref: 104] [Cited by in F6Publishing: 107] [Article Influence: 26.0] [Reference Citation Analysis]
125 Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TJ, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. JCO 2013;31:4453-61. [DOI: 10.1200/jco.2013.51.0826] [Cited by in Crossref: 113] [Cited by in F6Publishing: 59] [Article Influence: 12.6] [Reference Citation Analysis]
126 Driessen JP, Caldas-Magalhaes J, Janssen LM, Pameijer FA, Kooij N, Terhaard CH, Grolman W, Philippens ME. Diffusion-weighted MR imaging in laryngeal and hypopharyngeal carcinoma: association between apparent diffusion coefficient and histologic findings. Radiology 2014;272:456-63. [PMID: 24749712 DOI: 10.1148/radiol.14131173] [Cited by in Crossref: 89] [Cited by in F6Publishing: 81] [Article Influence: 11.1] [Reference Citation Analysis]
127 Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG, Ramsay AG, Kocher HM. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145:1121-1132. [PMID: 23891972 DOI: 10.1053/j.gastro.2013.07.025] [Cited by in Crossref: 260] [Cited by in F6Publishing: 256] [Article Influence: 28.9] [Reference Citation Analysis]
128 Thakur G, Kumar R, Kim SB, Lee SY, Lee SL, Rho GJ. Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma. Biomedicines 2021;9:178. [PMID: 33670230 DOI: 10.3390/biomedicines9020178] [Reference Citation Analysis]
129 Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res. 2013;73:3927-3937. [PMID: 23633481 DOI: 10.1158/0008-5472.can-12-4479] [Cited by in Crossref: 106] [Cited by in F6Publishing: 70] [Article Influence: 11.8] [Reference Citation Analysis]
130 Tang SC, Chen YC. Novel therapeutic targets for pancreatic cancer. World J Gastroenterol 2014; 20(31): 10825-10844 [PMID: 25152585 DOI: 10.3748/wjg.v20.i31.10825] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
131 Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J 2012;18:502-10. [PMID: 23187836 DOI: 10.1097/PPO.0b013e31827ab4c4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
132 Uzunparmak B, Sahin IH. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med 2019;8:2. [PMID: 30645701 DOI: 10.1186/s40169-019-0221-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
133 Prieto-García E, Díaz-García CV, Agudo-López A, Pardo-Marqués V, García-Consuegra I, Asensio-Peña S, Alonso-Riaño M, Pérez C, Gómez C, Adeva J, Paz-Ares L, López-Martín JA, Agulló-Ortuño MT. Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread. Biomedicines 2021;9:364. [PMID: 33807441 DOI: 10.3390/biomedicines9040364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Ernsting MJ, Hoang B, Lohse I, Undzys E, Cao P, Do T, Gill B, Pintilie M, Hedley D, Li SD. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. J Control Release. 2015;206:122-130. [PMID: 25804872 DOI: 10.1016/j.jconrel.2015.03.023] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
135 Celli JP, Solban N, Liang A, Pereira SP, Hasan T. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg Med. 2011;43:565-574. [PMID: 22057484 DOI: 10.1002/lsm.21093] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 6.0] [Reference Citation Analysis]
136 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
137 Kong X, Sun T, Kong F, Du Y, Li Z. Chronic Pancreatitis and Pancreatic Cancer. Gastrointest Tumors. 2014;1:123-134. [PMID: 26674754 DOI: 10.1159/000365306] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
138 Huang ZQ, Saluja AK, Dudeja V, Vickers SM, Buchsbaum DJ. Molecular targeted approaches for treatment of pancreatic cancer. Curr Pharm Des. 2011;17:2221-2238. [PMID: 21777178 DOI: 10.2174/138161211796957427] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
139 Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol 2014;16:865-78. [DOI: 10.1007/s12094-014-1177-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
140 Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, West NP, Wright AI, Treanor D, Hewitt LC, Allum WH, Cunningham D, Hayden JD, Grabsch HI. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget 2016;7:77565-75. [PMID: 27769054 DOI: 10.18632/oncotarget.12723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
141 Kim E, Choi S, Kang B, Kong J, Kim Y, Yoon WH, Lee H, Kim S, Kim H, Lee H, Yang C, Lee YJ, Kang M, Roh T, Jung S, Kim S, Ku JH, Shin K. Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature 2020;588:664-9. [DOI: 10.1038/s41586-020-3034-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
142 Du R, Sullivan DK, Azizian NG, Liu Y, Li Y. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells. BMC Cancer 2021;21:237. [PMID: 33676427 DOI: 10.1186/s12885-021-07967-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Yamamoto G, Taura K, Iwaisako K, Asagiri M, Ito S, Koyama Y, Tanabe K, Iguchi K, Satoh M, Nishio T, Okuda Y, Ikeno Y, Yoshino K, Seo S, Hatano E, Uemoto S. Pancreatic Stellate Cells Have Distinct Characteristics From Hepatic Stellate Cells and Are Not the Unique Origin of Collagen-Producing Cells in the Pancreas. Pancreas 2017;46:1141-51. [PMID: 28902784 DOI: 10.1097/MPA.0000000000000901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
144 Principe DR, Timbers KE, Atia LG, Koch RM, Rana A. TGFβ Signaling in the Pancreatic Tumor Microenvironment. Cancers (Basel) 2021;13:5086. [PMID: 34680235 DOI: 10.3390/cancers13205086] [Reference Citation Analysis]
145 Garajová I, Giovannetti E, Biasco G, Peters GJ. c-Met as a Target for Personalized Therapy. Transl Oncogenomics 2015;7:13-31. [PMID: 26628860 DOI: 10.4137/TOG.S30534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 46] [Article Influence: 1.9] [Reference Citation Analysis]
146 Wei Y, Wang Y, Xia D, Guo S, Wang F, Zhang X, Gan Y. Thermosensitive Liposomal Codelivery of HSA–Paclitaxel and HSA–Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer. ACS Appl Mater Interfaces 2017;9:25138-51. [DOI: 10.1021/acsami.7b07132] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
147 Golan T, Atias D, Barshack I, Avivi C, Goldstein RS, Berger R. Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine. Br J Cancer 2014;110:2269-76. [PMID: 24667644 DOI: 10.1038/bjc.2014.123] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
148 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
149 Dosch AR, Dai X, Reyzer ML, Mehra S, Srinivasan S, Willobee BA, Kwon D, Kashikar N, Caprioli R, Merchant NB, Nagathihalli NS. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Mol Cancer Res 2020;18:623-31. [PMID: 31949002 DOI: 10.1158/1541-7786.MCR-19-0741] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
150 Alexander J, Cukierman E. Cancer associated fibroblast: Mediators of tumorigenesis. Matrix Biol 2020;91-92:19-34. [PMID: 32450219 DOI: 10.1016/j.matbio.2020.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
151 Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H, Liu S, Yu G, Liu S, Beyaert R, Chang M, Li Q, Cao Y. Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis. JCI Insight 2018;3:122375. [PMID: 30333314 DOI: 10.1172/jci.insight.122375] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
152 Lundberg A, Li B, Li R. B cell-related gene signature and cancer immunotherapy response. Br J Cancer 2021. [PMID: 34921229 DOI: 10.1038/s41416-021-01674-6] [Reference Citation Analysis]
153 Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy 2015;7:363-76. [PMID: 25917628 DOI: 10.2217/imt.15.9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
154 Pausch TM, Aue E, Wirsik NM, Freire Valls A, Shen Y, Radhakrishnan P, Hackert T, Schneider M, Schmidt T. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Sci Rep 2020;10:5420. [PMID: 32214219 DOI: 10.1038/s41598-020-62416-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
155 Daman Z, Faghihi H, Montazeri H. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Dev Ind Pharm 2018;44:1434-42. [PMID: 29619850 DOI: 10.1080/03639045.2018.1459674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
156 Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med 2016;22:497-505. [PMID: 27089513 DOI: 10.1038/nm.4082] [Cited by in Crossref: 287] [Cited by in F6Publishing: 280] [Article Influence: 47.8] [Reference Citation Analysis]
157 Kiseleva AA, Korobeynikov VA, Nikonova AS, Zhang P, Makhov P, Deneka AY, Einarson MB, Serebriiskii IG, Liu H, Peterson JR, Golemis EA. Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs. Clin Cancer Res 2019;25:4179-93. [PMID: 30867219 DOI: 10.1158/1078-0432.CCR-18-3535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
158 Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017;9. [PMID: 29144412 DOI: 10.3390/cancers9110157] [Cited by in Crossref: 142] [Cited by in F6Publishing: 143] [Article Influence: 28.4] [Reference Citation Analysis]
159 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
160 Binenbaum Y, Na'ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55-68. [PMID: 26690340 DOI: 10.1016/j.drup.2015.10.002] [Cited by in Crossref: 118] [Cited by in F6Publishing: 128] [Article Influence: 16.9] [Reference Citation Analysis]
161 Tang D, Zhang J, Yuan Z, Gao J, Wang S, Ye N, Li P, Gao S, Miao Y, Wang D. Pancreatic satellite cells derived galectin-1 increase the progression and less survival of pancreatic ductal adenocarcinoma. PLoS One. 2014;9:e90476. [PMID: 24595374 DOI: 10.1371/journal.pone.0090476] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
162 Jiang X, Seo YD, Chang JH, Coveler A, Nigjeh EN, Pan S, Jalikis F, Yeung RS, Crispe IN, Pillarisetty VG. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Oncoimmunology 2017;6:e1333210. [PMID: 28811976 DOI: 10.1080/2162402X.2017.1333210] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
163 Hill KS, Gaziova I, Harrigal L, Guerra YA, Qiu S, Sastry SK, Arumugam T, Logsdon CD, Elferink LA. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS One 2012;7:e40420. [PMID: 22815748 DOI: 10.1371/journal.pone.0040420] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
164 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
165 Majety M, Pradel LP, Gies M, Ries CH. Fibroblasts Influence Survival and Therapeutic Response in a 3D Co-Culture Model. PLoS One 2015;10:e0127948. [PMID: 26053043 DOI: 10.1371/journal.pone.0127948] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
166 Shintakuya R, Kondo N, Murakami Y, Uemura K, Nakagawa N, Okano K, Takahashi S, Sueda T. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. Pancreatology 2018;18:191-7. [PMID: 29295776 DOI: 10.1016/j.pan.2017.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
167 Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest 2016;126:4140-56. [PMID: 27701147 DOI: 10.1172/JCI87734] [Cited by in Crossref: 107] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
168 Shi K, Xue B, Jia Y, Yuan L, Han R, Yang F, Peng J, Qian Z. Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer. Nano Res 2019;12:1389-99. [DOI: 10.1007/s12274-019-2342-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 8.3] [Reference Citation Analysis]
169 Vennin C, Rath N, Pajic M, Olson MF, Timpson P. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. Small GTPases 2020;11:45-52. [PMID: 28972449 DOI: 10.1080/21541248.2017.1345712] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
170 Wang S, Cai Y. Identification of the functional alteration signatures across different cancer types with support vector machine and feature analysis. Biochim Biophys Acta Mol Basis Dis 2018;1864:2218-27. [PMID: 29277326 DOI: 10.1016/j.bbadis.2017.12.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
171 Cheng XB, Sato N, Kohi S, Yamaguchi K. Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. PLoS One. 2013;8:e80765. [PMID: 24244714 DOI: 10.1371/journal.pone.0080765] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 7.0] [Reference Citation Analysis]
172 Wang H, Zhao Z, Lei S, Li S, Xiang Z, Wang X, Huang X, Xia G, Huang X. Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species. Cancer Cell Int 2019;19:7. [PMID: 30627053 DOI: 10.1186/s12935-018-0705-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
173 Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, Bekaii-Saab T, Lesinski GB. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67:320-332. [PMID: 27797936 DOI: 10.1136/gutjnl-2016-311585] [Cited by in Crossref: 202] [Cited by in F6Publishing: 200] [Article Influence: 33.7] [Reference Citation Analysis]
174 Hamada S, Masamune A, Yoshida N, Takikawa T, Shimosegawa T. IL-6/STAT3 Plays a Regulatory Role in the Interaction Between Pancreatic Stellate Cells and Cancer Cells. Dig Dis Sci 2016;61:1561-71. [PMID: 26738736 DOI: 10.1007/s10620-015-4001-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
175 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
176 de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8-16. [PMID: 25084222 DOI: 10.1016/j.ejphar.2014.07.041] [Cited by in Crossref: 258] [Cited by in F6Publishing: 242] [Article Influence: 32.3] [Reference Citation Analysis]
177 Principe DR, DeCant B, Diaz AM, Mangan RJ, Hwang R, Lowy A, Shetuni BB, Sreekumar BK, Chung C, Bentrem DJ, Munshi HG, Jung B, Grippo PJ, Bishehsari F. PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget 2016;7:28218-34. [PMID: 27058416 DOI: 10.18632/oncotarget.8587] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
178 Gore J, Craven KE, Wilson JL, Cote GA, Cheng M, Nguyen HV, Cramer HM, Sherman S, Korc M. TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget 2015;6:7504-21. [PMID: 25762644 DOI: 10.18632/oncotarget.3233] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
179 McDermott S, Thayer SP, Fernandez-Del Castillo C, Mino-Kenudson M, Weissleder R, Harisinghani MG. Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle. Transl Oncol 2013;6:670-5. [PMID: 24466369 DOI: 10.1593/tlo.13400] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
180 Kwegyir-Afful AK, Murigi FN, Purushottamachar P, Ramamurthy VP, Martin MS, Njar VCO. Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget 2017;8:52381-402. [PMID: 28881737 DOI: 10.18632/oncotarget.14154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
181 Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One. 2013;8:e71978. [PMID: 23991015 DOI: 10.1371/journal.pone.0071978] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 11.0] [Reference Citation Analysis]
182 Song H, Zhang Y. Regulation of pancreatic stellate cell activation by Notch3. BMC Cancer 2018;18:36. [PMID: 29304760 DOI: 10.1186/s12885-017-3957-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
183 Sun L, Zhang X, Song Q, Liu L, Forbes E, Tian W, Zhang Z, Kang Y, Wang H, Fleming JB, Pasche BC, Zhang W. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Lett 2021;500:132-46. [PMID: 33309859 DOI: 10.1016/j.canlet.2020.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
184 Cannon TL, Ford J, Hester D, Trump DL. The Incidental Use of High-Dose Vitamin D3 in Pancreatic Cancer. Case Rep Pancreat Cancer 2016;2:32-5. [PMID: 30631812 DOI: 10.1089/crpc.2016.0003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
185 Gupta J, Safdari HA, Hoque M. Nanoparticle mediated cancer immunotherapy. Semin Cancer Biol 2021;69:307-24. [PMID: 32259643 DOI: 10.1016/j.semcancer.2020.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
186 Wang L, Wang L, Wang S, Zhou Z, Liu Z, Xu P, Luo X, Wu T, Luo F, Yan J. N2E4, a Monoclonal Antibody Targeting Neuropilin-2, Inhibits Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma via Suppressing FAK/Erk/HIF-1α Signaling. Front Oncol 2021;11:657008. [PMID: 34336654 DOI: 10.3389/fonc.2021.657008] [Reference Citation Analysis]
187 Ehlen L, Arndt J, Treue D, Bischoff P, Loch FN, Hahn EM, Kotsch K, Klauschen F, Beyer K, Margonis GA, Kreis ME, Kamphues C. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. BMC Cancer. 2020;20:417. [PMID: 32404074 DOI: 10.1186/s12885-020-06929-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
188 Damia G, Garattini S. The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev 2014;40:909-16. [PMID: 24969326 DOI: 10.1016/j.ctrv.2014.05.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
189 Garcia PL, Miller AL, Yoon KJ. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers (Basel) 2020;12:E1327. [PMID: 32456018 DOI: 10.3390/cancers12051327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
190 Siret C, Collignon A, Silvy F, Robert S, Cheyrol T, André P, Rigot V, Iovanna J, van de Pavert S, Lombardo D, Mas E, Martirosyan A. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma. Front Immunol 2019;10:3070. [PMID: 32038621 DOI: 10.3389/fimmu.2019.03070] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
191 Hasselluhn MC, Klein L, Patzak MS, Buchholz SM, Ströbel P, Ellenrieder V, Maisonneuve P, Neesse A. Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer. Cells 2019;9:E58. [PMID: 31878349 DOI: 10.3390/cells9010058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
192 Overchuk M, Harmatys KM, Sindhwani S, Rajora MA, Koebel A, Charron DM, Syed AM, Chen J, Pomper MG, Wilson BC, Chan WCW, Zheng G. Subtherapeutic Photodynamic Treatment Facilitates Tumor Nanomedicine Delivery and Overcomes Desmoplasia. Nano Lett 2021;21:344-52. [PMID: 33301689 DOI: 10.1021/acs.nanolett.0c03731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
193 Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?Front Oncol. 2020;10:576399. [PMID: 33178608 DOI: 10.3389/fonc.2020.576399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
194 Schimmack S, Kneller S, Dadabaeva N, Bergmann F, Taylor A, Hackert T, Werner J, Strobel O. Epithelial to Stromal Re-Distribution of Primary Cilia during Pancreatic Carcinogenesis. PLoS One 2016;11:e0164231. [PMID: 27783689 DOI: 10.1371/journal.pone.0164231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
195 Kim SI, Shin JY, Park JS, Jeong S, Jeon YS, Choi MH, Choi HJ, Moon JH, Hwang JC, Yang MJ, Yoo BM, Kim JH, Lee HW, Kwon CI, Lee DH. Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer. Pancreatology 2017;17:103-8. [PMID: 27780664 DOI: 10.1016/j.pan.2016.10.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
196 Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J, Huang K. Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterol Res Pract 2016;2016:8962321. [PMID: 26941789 DOI: 10.1155/2016/8962321] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 10.2] [Reference Citation Analysis]
197 Mühlberg L, Kühnemuth B, Costello E, Shaw V, Sipos B, Huber M, Griesmann H, Krug S, Schober M, Gress TM, Michl P. miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. Oncoimmunology 2016;5:e1160181. [PMID: 27471627 DOI: 10.1080/2162402X.2016.1160181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
198 Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials 2018;156:217-37. [PMID: 29207323 DOI: 10.1016/j.biomaterials.2017.10.024] [Cited by in Crossref: 177] [Cited by in F6Publishing: 160] [Article Influence: 35.4] [Reference Citation Analysis]
199 Ma L, Han X, Gu J, Li J, Lou W, Jin C, Saiyin H. The physiological characteristics of the basal microvilli microvessels in pancreatic cancers. Cancer Med 2020;9:5535-45. [PMID: 32488986 DOI: 10.1002/cam4.3177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
200 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
201 Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther 2020;5:249. [PMID: 33122631 DOI: 10.1038/s41392-020-00341-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
202 Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R. Soluble stroma-related biomarkers of pancreatic cancer. EMBO Mol Med 2018;10:e8741. [PMID: 29941541 DOI: 10.15252/emmm.201708741] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
203 Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One. 2012;7:e49145. [PMID: 23155457 DOI: 10.1371/journal.pone.0049145] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
204 Alhakamy NA, Ahmed OAA, Fahmy UA, Md S. Apamin-Conjugated Alendronate Sodium Nanocomplex for Management of Pancreatic Cancer. Pharmaceuticals (Basel) 2021;14:729. [PMID: 34451826 DOI: 10.3390/ph14080729] [Reference Citation Analysis]
205 Aseem SO, Huebert RC. Epigenetic Mechanisms of Pancreatobiliary Fibrosis. Curr Treat Options Gastroenterol 2019;17:342-56. [PMID: 31300946 DOI: 10.1007/s11938-019-00239-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Sousa CM, Kimmelman AC. The complex landscape of pancreatic cancer metabolism. Carcinogenesis. 2014;35:1441-1450. [PMID: 24743516 DOI: 10.1093/carcin/bgu097] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
207 Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, Melenec P, Walters SN, Del Monte-Nieto G, Conway JR, Nobis M, Allam AH, McCloy RA, Currey N, Pinese M, Boulghourjian A, Zaratzian A, Adam AA, Heu C, Nagrial AM, Chou A, Steinmann A, Drury A, Froio D, Giry-Laterriere M, Harris NL, Phan T, Jain R, Weninger W, McGhee EJ, Whan R, Johns AL, Samra JS, Chantrill L, Gill AJ, Kohonen-Corish M, Harvey RP, Biankin AV, Evans TR, Anderson KI, Grey ST, Ormandy CJ, Gallego-Ortega D, Wang Y, Samuel MS, Sansom OJ, Burgess A, Cox TR, Morton JP, Pajic M, Timpson P; Australian Pancreatic Cancer Genome Initiative (APGI). Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med 2017;9:eaai8504. [PMID: 28381539 DOI: 10.1126/scitranslmed.aai8504] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 27.8] [Reference Citation Analysis]
208 Strand MF, Wilson SR, Dembinski JL, Holsworth DD, Khvat A, Okun I, Petersen D, Krauss S. A novel synthetic smoothened antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model. PLoS One 2011;6:e19904. [PMID: 21698280 DOI: 10.1371/journal.pone.0019904] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
209 Hecht EM, Liu MZ, Prince MR, Jambawalikar S, Remotti HE, Weisberg SW, Garmon D, Lopez-Pintado S, Woo Y, Kluger MD, Chabot JA. Can diffusion-weighted imaging serve as a biomarker of fibrosis in pancreatic adenocarcinoma? J Magn Reson Imaging 2017;46:393-402. [PMID: 28152252 DOI: 10.1002/jmri.25581] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
210 González-Borja I, Viúdez A, Goñi S, Santamaria E, Carrasco-García E, Pérez-Sanz J, Hernández-García I, Sala-Elarre P, Arrazubi V, Oyaga-Iriarte E, Zárate R, Arévalo S, Sayar O, Vera R, Fernández-Irigoyen J. Omics Approaches in Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1052. [PMID: 31349663 DOI: 10.3390/cancers11081052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
211 Tjomsland V, Sandnes D, Pomianowska E, Cizmovic ST, Aasrum M, Brusevold IJ, Christoffersen T, Gladhaug IP. The TGFβ-SMAD3 pathway inhibits IL-1α induced interactions between human pancreatic stellate cells and pancreatic carcinoma cells and restricts cancer cell migration. J Exp Clin Cancer Res 2016;35:122. [PMID: 27473228 DOI: 10.1186/s13046-016-0400-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
212 Cui Y, Brosnan JA, Blackford AL, Sur S, Hruban RH, Kinzler KW, Vogelstein B, Maitra A, Diaz LA Jr, Iacobuzio-Donahue CA, Eshleman JR. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 2012;18:6519-30. [PMID: 22753594 DOI: 10.1158/1078-0432.CCR-12-0827] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
213 Goetze RG, Buchholz SM, Ou N, Zhang Q, Patil S, Schirmer M, Singh SK, Ellenrieder V, Hessmann E, Lu QB, Neesse A. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Cells 2019;8:E563. [PMID: 31181844 DOI: 10.3390/cells8060563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
214 Goodwin ML, Urs SK, Simeone DM. Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform. Methods Mol Biol 2019;1882:73-80. [PMID: 30378045 DOI: 10.1007/978-1-4939-8879-2_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
215 Chen J, Weihs D, Vermolen FJ. Computational modeling of therapy on pancreatic cancer in its early stages. Biomech Model Mechanobiol 2020;19:427-44. [PMID: 31501963 DOI: 10.1007/s10237-019-01219-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
216 Lonardo E, Hermann P, Mueller M, Huber S, Balic A, Miranda-lorenzo I, Zagorac S, Alcala S, Rodriguez-arabaolaza I, Ramirez J, Torres-ruíz R, Garcia E, Hidalgo M, Cebrián D, Heuchel R, Löhr M, Berger F, Bartenstein P, Aicher A, Heeschen C. Nodal/Activin Signaling Drives Self-Renewal and Tumorigenicity of Pancreatic Cancer Stem Cells and Provides a Target for Combined Drug Therapy. Cell Stem Cell 2011;9:433-46. [DOI: 10.1016/j.stem.2011.10.001] [Cited by in Crossref: 273] [Cited by in F6Publishing: 251] [Article Influence: 24.8] [Reference Citation Analysis]
217 Brock A, Krause S, Ingber DE. Control of cancer formation by intrinsic genetic noise and microenvironmental cues. Nat Rev Cancer 2015;15:499-509. [DOI: 10.1038/nrc3959] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
218 Lai SW, Bamodu OA, Tsai WC, Chang YM, Lee WH, Yeh CT, Chao TY. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity. Clin Exp Metastasis 2018;35:663-77. [PMID: 29987671 DOI: 10.1007/s10585-018-9919-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
219 Cappello P, Tonoli E, Curto R, Giordano D, Giovarelli M, Novelli F. Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response. Oncoimmunology 2016;5:e1112940. [PMID: 27467915 DOI: 10.1080/2162402X.2015.1112940] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
220 Osborne N, Sundseth R, Burks J, Cao H, Liu X, Kroemer AH, Sutton L, Cato A, Smith JP. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunol Immunother 2019;68:1635-48. [PMID: 31549214 DOI: 10.1007/s00262-019-02398-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
221 Huo D, Jiang X, Hu Y. Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management. Adv Mater 2020;32:e1904337. [PMID: 31663198 DOI: 10.1002/adma.201904337] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
222 Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037] [Reference Citation Analysis]
223 Coleman S, Bruce C, Chioni A, Kocher H, Grose R. The ins and outs of fibroblast growth factor receptor signalling. Clinical Science 2014;127:217-31. [DOI: 10.1042/cs20140100] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
224 Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. 2014;63:974-983. [PMID: 24067278 DOI: 10.1136/gutjnl-2013-305559] [Cited by in Crossref: 96] [Cited by in F6Publishing: 124] [Article Influence: 10.7] [Reference Citation Analysis]
225 He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y, Chen Q, Ruan C, Guo Q, Li C, Sun T, Jiang C. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Adv Sci (Weinh) 2018;5:1701070. [PMID: 29876225 DOI: 10.1002/advs.201701070] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
226 Garajová I, Giovannetti E, Biasco G, Peters GJ. c-Met as a Target for Personalized Therapy. Transl Oncogenomics. 2015;7:13-31. [PMID: 26628860 DOI: 10.4137/togog.s30534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
227 Datta R, Sivanand S, Lau AN, Florek LV, Barbeau AM, Wyckoff J, Skala MC, Vander Heiden MG. Interactions with stromal cells promote a more oxidized cancer cell redox state in pancreatic tumors. Sci Adv 2022;8:eabg6383. [DOI: 10.1126/sciadv.abg6383] [Reference Citation Analysis]
228 Duan W, Chen K, Jiang Z, Chen X, Sun L, Li J, Lei J, Xu Q, Ma J, Li X, Han L, Wang Z, Wu Z, Wang F, Wu E, Ma Q, Ma Z. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Cancer Lett 2017;385:225-33. [PMID: 27773749 DOI: 10.1016/j.canlet.2016.10.019] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
229 Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochemical Pharmacology 2013;85:1033-41. [DOI: 10.1016/j.bcp.2013.01.018] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 9.4] [Reference Citation Analysis]
230 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
231 Boland AJ, O'Kane AA, Buick R, Longley DB, Scott CJ. Antibody therapy in pancreatic cancer: mAb-ye we're onto something? Biochim Biophys Acta Rev Cancer 2021;1876:188557. [PMID: 33945846 DOI: 10.1016/j.bbcan.2021.188557] [Reference Citation Analysis]
232 You J, Zhao J, Wen X, Wu C, Huang Q, Guan F, Wu R, Liang D, Li C. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles. J Control Release 2015;202:40-8. [PMID: 25637565 DOI: 10.1016/j.jconrel.2015.01.031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
233 Bunggulawa EJ, Wang W, Yin T, Wang N, Durkan C, Wang Y, Wang G. Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnology. 2018;16:81. [PMID: 30326899 DOI: 10.1186/s12951-018-0403-9] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 39.8] [Reference Citation Analysis]
234 Yang Y, Bteich J, Li SD. Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors. AAPS J 2017;19:386-96. [PMID: 27873118 DOI: 10.1208/s12248-016-0014-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
235 Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014;8:1905-1918. [PMID: 25242334 DOI: 10.1016/j.celrep.2014.08.029.single-cell] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
236 Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 226] [Article Influence: 40.2] [Reference Citation Analysis]
237 Baues M, Dasgupta A, Ehling J, Prakash J, Boor P, Tacke F, Kiessling F, Lammers T. Fibrosis imaging: Current concepts and future directions. Adv Drug Deliv Rev 2017;121:9-26. [PMID: 29108860 DOI: 10.1016/j.addr.2017.10.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 12.6] [Reference Citation Analysis]
238 Chen Z, Chen LY, Wang P, Dai HY, Gao S, Wang K. Tumor Microenvironment Varies under Different TCM ZHENG Models and Correlates with Treatment Response to Herbal Medicine. Evid Based Complement Alternat Med 2012;2012:635702. [PMID: 22690248 DOI: 10.1155/2012/635702] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
239 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503-1523. [PMID: 25071162 DOI: 10.1084/jem.20140692] [Cited by in Crossref: 423] [Cited by in F6Publishing: 418] [Article Influence: 52.9] [Reference Citation Analysis]
240 Amrutkar M, Aasrum M, Verbeke CS, Gladhaug IP. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. BMC Cancer 2019;19:596. [PMID: 31208372 DOI: 10.1186/s12885-019-5803-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
241 Neuzillet C, Couvelard A, Tijeras-Raballand A, de Mestier L, de Gramont A, Bédossa P, Paradis V, Sauvanet A, Bachet JB, Ruszniewski P. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015;67:664-676. [PMID: 25809563 DOI: 10.1111/his.12691] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
242 Donahue TR, Dawson DW. Nodal/Activin signaling: a novel target for pancreatic cancer stem cell therapy. Cell Stem Cell 2011;9:383-4. [PMID: 22056131 DOI: 10.1016/j.stem.2011.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
243 Viloria K, Munasinghe A, Asher S, Bogyere R, Jones L, Hill NJ. A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth. Sci Rep 2016;6:37839. [PMID: 27886258 DOI: 10.1038/srep37839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
244 Morshedi Rad D, Alsadat Rad M, Razavi Bazaz S, Kashaninejad N, Jin D, Ebrahimi Warkiani M. A Comprehensive Review on Intracellular Delivery. Adv Mater 2021;33:e2005363. [PMID: 33594744 DOI: 10.1002/adma.202005363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
245 Nishida Y, Nagatsuma AK, Kojima M, Gotohda N, Ochiai A. Novel stromal biomarker screening in pancreatic cancer patients using the in vitro cancer-stromal interaction model. BMC Gastroenterol 2020;20:411. [PMID: 33297976 DOI: 10.1186/s12876-020-01556-w] [Reference Citation Analysis]
246 Perik TH, van Genugten EAJ, Aarntzen EHJG, Smit EJ, Huisman HJ, Hermans JJ. Quantitative CT perfusion imaging in patients with pancreatic cancer: a systematic review. Abdom Radiol (NY) 2021. [PMID: 34223961 DOI: 10.1007/s00261-021-03190-w] [Reference Citation Analysis]
247 Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014;124:1525-1536. [PMID: 24614108 DOI: 10.1172/jci73455] [Cited by in Crossref: 121] [Cited by in F6Publishing: 89] [Article Influence: 15.1] [Reference Citation Analysis]
248 Torres C, Perales S, Alejandre MJ, Iglesias J, Palomino RJ, Martin M, Caba O, Prados JC, Aránega A, Delgado JR, Irigoyen A, Ortuño FM, Rojas I, Linares A. Serum cytokine profile in patients with pancreatic cancer. Pancreas 2014;43:1042-9. [PMID: 24979617 DOI: 10.1097/MPA.0000000000000155] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
249 Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:77-87. [PMID: 22183185 DOI: 10.1038/nrgastro.2011.215] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
250 Suh HN, Jun S, Oh AY, Srivastava M, Lee S, Taniguchi CM, Zhang S, Lee WS, Chen J, Park BJ, Park JI. Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Sci Rep 2016;6:38273. [PMID: 27922049 DOI: 10.1038/srep38273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
251 Berchtold S, Grünwald B, Krüger A, Reithmeier A, Hähl T, Cheng T, Feuchtinger A, Born D, Erkan M, Kleeff J, Esposito I. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Cancer Lett 2015;356:721-32. [PMID: 25449434 DOI: 10.1016/j.canlet.2014.10.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
252 van der Sijde F, Homs MYV, van Bekkum ML, van den Bosch TPP, Bosscha K, Besselink MG, Bonsing BA, de Groot JWB, Karsten TM, Groot Koerkamp B, Haberkorn BCM, Luelmo SAC, Mekenkamp LJM, Mustafa DAM, Wilmink JW, van Eijck CHJ, Vietsch EE, On Behalf Of The Dutch Pancreatic Cancer Group. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. Int J Mol Sci 2021;22:10902. [PMID: 34681562 DOI: 10.3390/ijms222010902] [Reference Citation Analysis]
253 Xue A, Julovi SM, Hugh TJ, Samra JS, Wong MH, Gill AJ, Toon CW, Smith RC. A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. Pancreatology 2015;15:397-404. [PMID: 26026767 DOI: 10.1016/j.pan.2015.04.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
254 Takino JI, Sato T, Hiraishi I, Nagamine K, Hori T. Alterations in Glucose Metabolism Due to Decreased Expression of Heterogeneous Nuclear Ribonucleoprotein M in Pancreatic Ductal Adenocarcinoma. Biology (Basel) 2021;10:57. [PMID: 33466816 DOI: 10.3390/biology10010057] [Reference Citation Analysis]
255 Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
256 Tang D, Gao J, Wang S, Yuan Z, Ye N, Chong Y, Xu C, Jiang X, Li B, Yin W. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumour Biol. 2015;36:5617-5626. [PMID: 25725585 DOI: 10.1007/s13277-015-3233-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
257 Huang J, Agoston AT, Guo P, Moses MA. A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer. Adv Sci (Weinh) 2020;7:2002852. [PMID: 33344137 DOI: 10.1002/advs.202002852] [Reference Citation Analysis]
258 Cox MC, Reese LM, Bickford LR, Verbridge SS. Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline. ACS Biomater Sci Eng 2015;1:877-94. [DOI: 10.1021/acsbiomaterials.5b00172] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
259 Lou C, Lu H, Ma Z, Liu C, Zhang Y. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway. Biomedicine & Pharmacotherapy 2019;109:563-72. [DOI: 10.1016/j.biopha.2018.10.084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
260 Heneberg P. Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. Crit Rev Oncol Hematol. 2016;97:303-311. [PMID: 26467073 DOI: 10.1016/j.critrevonc.2015.09.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
261 Wu QY, Yang CK, Rong LJ, Li JC, Lei LM. Investigation of the association between C-X-C motif chemokine receptor subunits and tumor infiltration levels and prognosis in patients with early-stage pancreatic ductal adenocarcinoma. Oncol Lett 2020;20:16. [PMID: 32774489 DOI: 10.3892/ol.2020.11877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
262 van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
263 Yu M, Tannock IF. Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 2012;21:327-9. [PMID: 22439929 DOI: 10.1016/j.ccr.2012.03.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
264 Ware MJ, Keshishian V, Law JJ, Ho JC, Favela CA, Rees P, Smith B, Mohammad S, Hwang RF, Rajapakshe K, Coarfa C, Huang S, Edwards DP, Corr SJ, Godin B, Curley SA. Generation of an in vitro 3D PDAC stroma rich spheroid model. Biomaterials 2016;108:129-42. [PMID: 27627810 DOI: 10.1016/j.biomaterials.2016.08.041] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 10.8] [Reference Citation Analysis]
265 Loveday BP, Zilbert N, Serrano PE, Tomiyama K, Tremblay A, Fox AM, Segedi M, O'malley M, Borgida A, Bianco T, Creighton S, Dodd A, Fraser A, Moore M, Kim J, Cleary S, Moulton C, Greig P, Wei AC, Gallinger S, Dhani N, Mcgilvray ID. Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas. HPB 2019;21:643-52. [DOI: 10.1016/j.hpb.2018.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
266 Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017; 9(7): 281-292 [PMID: 28808501 DOI: 10.4251/wjgo.v9.i7.281] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
267 Steele CW, Jamieson NB, Carter CR. Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities. In: Wondrak GT, editor. Stress Response Pathways in Cancer. Dordrecht: Springer Netherlands; 2015. pp. 375-95. [DOI: 10.1007/978-94-017-9421-3_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
268 Karimnia V, Slack FJ, Celli JP. Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4354. [PMID: 34503165 DOI: 10.3390/cancers13174354] [Reference Citation Analysis]
269 Lesina M, Wörmann SM, Neuhöfer P, Song L, Algül H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Seminars in Immunology 2014;26:80-7. [DOI: 10.1016/j.smim.2014.01.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
270 Storz P. Targeting protein kinase C subtypes in pancreatic cancer. Expert Rev Anticancer Ther 2015;15:433-8. [PMID: 25604078 DOI: 10.1586/14737140.2015.1003810] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
271 Li T, Wan M, Mao C. Research Progress of Micro/Nanomotors for Cancer Treatment. Chempluschem 2020;85:2586-98. [PMID: 33174354 DOI: 10.1002/cplu.202000532] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
272 Jones B, Thomas G, Sprenger J, Nofech-Mozes S, Khorasani M, Vitkin A. Peri-tumoural stroma collagen organization of invasive ductal carcinoma assessed by polarized light microscopy differs between OncotypeDX risk group. J Biophotonics 2020;13:e202000188. [PMID: 32710711 DOI: 10.1002/jbio.202000188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Drifka CR, Loeffler AG, Mathewson K, Keikhosravi A, Eickhoff JC, Liu Y, Weber SM, Kao WJ, Eliceiri KW. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 2016;7:76197-213. [PMID: 27776346 DOI: 10.18632/oncotarget.12772] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 20.8] [Reference Citation Analysis]
274 Amrutkar M, Gladhaug IP. Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer. Cancers (Basel) 2021;13:601. [PMID: 33546284 DOI: 10.3390/cancers13040601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
275 Li Q, Wang H, Zogopoulos G, Shao Q, Dong K, Lv F, Nwilati K, Gui XY, Cuggia A, Liu JL, Gao ZH. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:77838-77853. [PMID: 27788482 DOI: 10.18632/oncotarget.12834] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
276 Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol 2020;215:610-6. [PMID: 32755156 DOI: 10.2214/AJR.19.22462] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
277 Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA, Soonawalla Z, Liu S, McKenna WG, Muschel RJ, Fokas E. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:40992-41004. [PMID: 27329602 DOI: 10.18632/oncotarget.10038] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
278 Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, Srivastava S, Frazier ML, Sen S, Hollingsworth MA, Rinaudo JA, Killary AM, Brand RE. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS One 2015;10:e0139049. [PMID: 26431551 DOI: 10.1371/journal.pone.0139049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
279 Ji T, Li S, Zhang Y, Lang J, Ding Y, Zhao X, Zhao R, Li Y, Shi J, Hao J. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. ACS Appl Mater Interfaces. 2016;8:3438-3445. [PMID: 26759926 DOI: 10.1021/acsami.5b11619] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 13.0] [Reference Citation Analysis]
280 Polasek M, Yang Y, Schühle DT, Yaseen MA, Kim YR, Sung YS, Guimaraes AR, Caravan P. Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Sci Rep 2017;7:8114. [PMID: 28808290 DOI: 10.1038/s41598-017-08838-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
281 Grizzi F, Fiorino S, Qehajaj D, Fornelli A, Russo C, de Biase D, Masetti M, Mastrangelo L, Zanello M, Lombardi R, Domanico A, Accogli E, Tura A, Mirandola L, Chiriva-Internati M, Bresalier RS, Jovine E, Leandri P, Di Tommaso L. Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study. J Transl Med 2019;17:61. [PMID: 30819202 DOI: 10.1186/s12967-019-1817-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
282 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
283 Anthes LE, Hajizadeh M. Socioeconomic inequalities in pancreatic cancer incidence in Canada: evidence from Cancer Registry data. J Public Health (Berl ). [DOI: 10.1007/s10389-020-01360-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Loc WS, Linton SS, Wilczynski ZR, Matters GL, McGovern CO, Abraham T, Fox T, Gigliotti CM, Tang X, Tabakovic A, Martin JA, Clawson GA, Smith JP, Butler PJ, Kester M, Adair JH. Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer. Nanomedicine 2017;13:2313-24. [PMID: 28673852 DOI: 10.1016/j.nano.2017.06.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
285 Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, Sicklick J, Nishihara H, Lowy AM, Insel PA. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J 2018;32:1170-83. [PMID: 29092903 DOI: 10.1096/fj.201700834R] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
286 Harmsen S, Huang R, Wall MA, Karabeber H, Samii JM, Spaliviero M, White JR, Monette S, O'Connor R, Pitter KL, Sastra SA, Saborowski M, Holland EC, Singer S, Olive KP, Lowe SW, Blasberg RG, Kircher MF. Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. Sci Transl Med 2015;7:271ra7. [PMID: 25609167 DOI: 10.1126/scitranslmed.3010633] [Cited by in Crossref: 154] [Cited by in F6Publishing: 146] [Article Influence: 22.0] [Reference Citation Analysis]
287 Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91-100. [PMID: 24388967 DOI: 10.1016/j.tibs.2013.12.004] [Cited by in Crossref: 375] [Cited by in F6Publishing: 348] [Article Influence: 46.9] [Reference Citation Analysis]
288 Wörmann SM, Algül H. Risk Factors and Therapeutic Targets in Pancreatic Cancer. Front Oncol 2013;3. [DOI: 10.3389/fonc.2013.00282] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
289 Chung S, Vail P, Witkiewicz AK, Knudsen ES. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer. Clin Cancer Res 2019;25:2290-304. [PMID: 30538111 DOI: 10.1158/1078-0432.CCR-18-1620] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
290 Imlimthan S, Moon ES, Rathke H, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E. New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. Pharmaceuticals (Basel) 2021;14:1023. [PMID: 34681246 DOI: 10.3390/ph14101023] [Reference Citation Analysis]
291 Maloney E, Hwang JH. Emerging HIFU applications in cancer therapy. Int J Hyperthermia 2015;31:302-9. [PMID: 25367011 DOI: 10.3109/02656736.2014.969789] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 10.1] [Reference Citation Analysis]
292 Oweida AJ, Mueller AC, Piper M, Milner D, Van Court B, Bhatia S, Phan A, Bickett T, Jordan K, Proia T, Schulick R, Messersmith WA, Del Chiaro M, Clambey E, Gough MJ, Williams J, Hansen K, Goodman K, Karam SD. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunol Immunother 2021;70:989-1000. [PMID: 33097963 DOI: 10.1007/s00262-020-02701-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
293 Maehira H, Miyake T, Iida H, Tokuda A, Mori H, Yasukawa D, Mukaisho KI, Shimizu T, Tani M. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population. Ann Surg Oncol 2019;26:4791-804. [PMID: 31583548 DOI: 10.1245/s10434-019-07891-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
294 Karabasz A, Bzowska M, Szczepanowicz K. Biomedical Applications of Multifunctional Polymeric Nanocarriers: A Review of Current Literature. Int J Nanomedicine 2020;15:8673-96. [PMID: 33192061 DOI: 10.2147/IJN.S231477] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
295 Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476-1484. [PMID: 25994217 DOI: 10.1136/gutjnl-2015-309304] [Cited by in Crossref: 281] [Cited by in F6Publishing: 275] [Article Influence: 40.1] [Reference Citation Analysis]
296 Collins AL, Rock J, Malhotra L, Frankel WL, Bloomston M. Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2012;19:2673-8. [PMID: 22461132 DOI: 10.1245/s10434-012-2337-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
297 Piehler S, Wucherpfennig L, Tansi FL, Berndt A, Quaas R, Teichgraeber U, Hilger I. Hyperthermia affects collagen fiber architecture and induces apoptosis in pancreatic and fibroblast tumor hetero-spheroids in vitro. Nanomedicine 2020;28:102183. [PMID: 32222478 DOI: 10.1016/j.nano.2020.102183] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
298 Ghanaatgar-kasbi S, Khorrami S, Avan A, Aledavoud SA, Ferns GA. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma. CPD 2019;24:4619-25. [DOI: 10.2174/1381612825666190110145855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
299 Wang J, Chai J, Liu L, Cui Z, Duan D, Shi R, Zhang Y. Dual-functional melanin-based nanoliposomes for combined chemotherapy and photothermal therapy of pancreatic cancer. RSC Adv 2019;9:3012-9. [DOI: 10.1039/c8ra09420a] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
300 Rebelo R, Polónia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 2021;14:280. [PMID: 33804613 DOI: 10.3390/ph14030280] [Reference Citation Analysis]
301 Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, Hattori M, Mizumoto K, Tanaka M, Oda Y. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer 2013;12:168. [PMID: 24354864 DOI: 10.1186/1476-4598-12-168] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 8.1] [Reference Citation Analysis]
302 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
303 Caceres J, Munoz-Sagastibelza M, Hossian AKMN, Paredes J, Barrera K, Mattheolabakis G, Martello LA, Vignesh S. Evaluation of the feasibility of intrapancreatic delivery of drug-loaded microparticles via EUS-guided fine needle injection using a swine model. Endosc Int Open 2019;7:E1008-17. [PMID: 31404394 DOI: 10.1055/a-0953-2070] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
305 Huang H, Kovacs ME, Y. Aguilera K, Brekken RA. Collagen Signaling in Cancer. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Elsevier; 2019. pp. 89-108. [DOI: 10.1016/b978-0-12-816435-8.00007-9] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
306 Zhu Z, Achreja A, Meurs N, Animasahun O, Owen S, Mittal A, Parikh P, Lo TW, Franco-Barraza J, Shi J, Gunchick V, Sherman MH, Cukierman E, Pickering AM, Maitra A, Sahai V, Morgan MA, Nagrath S, Lawrence TS, Nagrath D. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Nat Metab 2020;2:775-92. [PMID: 32694827 DOI: 10.1038/s42255-020-0226-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
307 Wu Q, Tian Y, Zhang J, Zhang H, Gu F, Lu Y, Zou S, Chen Y, Sun P, Xu M, Sun X, Xia C, Chi H, Ying Zhu A, Tang D, Wang D. Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. Oncotarget 2017;8:102721-38. [PMID: 29254283 DOI: 10.18632/oncotarget.21970] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
308 Singh A, Xu J, Mattheolabakis G, Amiji M. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. Nanomedicine 2016;12:589-600. [PMID: 26656632 DOI: 10.1016/j.nano.2015.11.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
309 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
310 D'Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, Graziano P, Pazienza V. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget 2015;6:18545-57. [PMID: 26176887 DOI: 10.18632/oncotarget.4186] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
311 Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clin Cancer Res. 2017;23:4429-4440. [PMID: 28348045 DOI: 10.1158/1078-0432.ccr-17-0162] [Cited by in Crossref: 85] [Cited by in F6Publishing: 59] [Article Influence: 17.0] [Reference Citation Analysis]
312 Suri R, Zimmerman JW, Burkhart RA. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. Ann Pancreat Cancer 2020;3:17. [PMID: 33889840 DOI: 10.21037/apc-20-29] [Reference Citation Analysis]
313 Drifka CR, Tod J, Loeffler AG, Liu Y, Thomas GJ, Eliceiri KW, Kao WJ. Periductal stromal collagen topology of pancreatic ductal adenocarcinoma differs from that of normal and chronic pancreatitis. Mod Pathol 2015;28:1470-80. [DOI: 10.1038/modpathol.2015.97] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
314 Alemany R. Chapter four--Design of improved oncolytic adenoviruses. Adv Cancer Res 2012;115:93-114. [PMID: 23021243 DOI: 10.1016/B978-0-12-398342-8.00004-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
315 Wu H, Zhu L, Zhang H, Shi X, Zhang L, Wang W, Xue H, Liang Z. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. PLoS One 2015;10:e0116803. [PMID: 25679210 DOI: 10.1371/journal.pone.0116803] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
316 Biondani G, Zeeberg K, Greco MR, Cannone S, Dando I, Dalla Pozza E, Mastrodonato M, Forciniti S, Casavola V, Palmieri M. Extracellular matrix composition modulates PDAC parenchymal and stem cell plasticity and behavior through the secretome. FEBS J. 2018;285:2104-2124. [PMID: 29660229 DOI: 10.1111/febs.14471] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
317 Diana A, Wang LM, D'Costa Z, Azad A, Silva MA, Soonawalla Z, Allen P, Liu S, McKenna WG, Muschel RJ, Fokas E. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:72819-32. [PMID: 27637082 DOI: 10.18632/oncotarget.12022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
318 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
319 Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, Qin Y, Xu J, Ni Q, Yu X. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Exp Mol Med 2017;49:e406. [PMID: 29611542 DOI: 10.1038/emm.2017.255] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
320 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015;5:1040-1048. [PMID: 26109333 DOI: 10.1158/2159-8290.cd-15-0274.cell-free] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
321 Farr N, Wang YN, D'Andrea S, Gravelle KM, Hwang JH, Lee D. Noninvasive characterization of pancreatic tumor mouse models using magnetic resonance imaging. Cancer Med. 2017;6:1082-1090. [PMID: 28390098 DOI: 10.1002/cam4.1062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
322 Puig-Saus C, Laborda E, Rodríguez-García A, Cascalló M, Moreno R, Alemany R. The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model. Cancer Gene Ther 2014;21:68-73. [PMID: 24434571 DOI: 10.1038/cgt.2013.85] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
323 Westphalen CB, Marrache F, Wang TC. Analysis of transplanted bone marrow-derived cells in chronic pancreatitis. Methods Mol Biol 2013;980:291-300. [PMID: 23359161 DOI: 10.1007/978-1-62703-287-2_16] [Reference Citation Analysis]
324 Ramu I, Buchholz SM, Patzak MS, Goetze RG, Singh SK, Richards FM, Jodrell DI, Sipos B, Ströbel P, Ellenrieder V, Hessmann E, Neesse A. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer. EBioMedicine 2019;48:161-8. [PMID: 31597597 DOI: 10.1016/j.ebiom.2019.09.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
325 Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, Qin Y, Xu J, Ni Q, Yu X. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Cell Mol Life Sci 2018;75:1001-12. [DOI: 10.1007/s00018-017-2678-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
326 Vazquez A, Kamphorst JJ, Markert EK, Schug ZT, Tardito S, Gottlieb E. Cancer metabolism at a glance. J Cell Sci 2016;129:3367-73. [PMID: 27635066 DOI: 10.1242/jcs.181016] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 18.4] [Reference Citation Analysis]
327 Di-Luoffo M, Ben-Meriem Z, Lefebvre P, Delarue M, Guillermet-Guibert J. PI3K functions as a hub in mechanotransduction. Trends Biochem Sci 2021:S0968-0004(21)00108-0. [PMID: 34112586 DOI: 10.1016/j.tibs.2021.05.005] [Reference Citation Analysis]
328 Suenaga M, Yamada S, Fujii T, Tanaka C, Kanda M, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J Surg Oncol. 2016;113:413-419. [PMID: 27100026 DOI: 10.1002/jso.24147] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
329 Leppänen J, Lindholm V, Isohookana J, Haapasaari KM, Karihtala P, Lehenkari PP, Saarnio J, Kauppila JH, Karttunen TJ, Helminen O, Huhta H. Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Pancreas 2019;48:43-8. [PMID: 30451798 DOI: 10.1097/MPA.0000000000001195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
330 Cui J, Xia T, Xie D, Gao Y, Jia Z, Wei D, Wang L, Huang S, Quan M, Xie K. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes. Oncogene 2016;35:4708-18. [PMID: 26876216 DOI: 10.1038/onc.2016.14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
331 Leal AS, Misek SA, Lisabeth EM, Neubig RR, Liby KT. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Sci Rep 2019;9:7072. [PMID: 31068602 DOI: 10.1038/s41598-019-43430-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
332 Dimou A, Syrigos KN, Saif MW. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol 2012;4:271-9. [PMID: 22942909 DOI: 10.1177/1758834012446008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
333 Keire PA, Kang I, Wight TN. Versican: Role in Cancer Tumorigenesis. In: Brekken RA, Stupack D, editors. Extracellular Matrix in Tumor Biology. Cham: Springer International Publishing; 2017. pp. 51-74. [DOI: 10.1007/978-3-319-60907-2_4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Matters GL, Clawson GA. A Speculative Role for Stromal Gastrin Signaling in Development and Dissemination of Pancreatic Ductal Adenocarcinoma. Pancreat Disord Ther 2013;Suppl 4:003. [PMID: 25346875 DOI: 10.4172/2165-7092.S4-003] [Reference Citation Analysis]
335 de Sousa Cavalcante L, Costa-Silva TA, Souza TA, Ienne S, Monteiro G. Chemogenomic study of gemcitabine using Saccharomyces cerevisiae as model cell-molecular insights about chemoresistance. Braz J Microbiol 2020;51:489-96. [PMID: 31515725 DOI: 10.1007/s42770-019-00154-7] [Reference Citation Analysis]
336 Matkar PN, Jong ED, Ariyagunarajah R, Prud'homme GJ, Singh KK, Leong-Poi H. Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer. Cancer Med 2018;7:5036-46. [PMID: 30216699 DOI: 10.1002/cam4.1715] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
337 Hexige S, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, Han X, Li J, Zhou P, Yi Q, Maitra A, Liu JO, Tuveson DA, Lou W, Yu L. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. J Pathol 2015;236:142-54. [PMID: 25561062 DOI: 10.1002/path.4506] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
338 Rahal A, Musher B. Oncolytic viral therapy for pancreatic cancer. J Surg Oncol 2017;116:94-103. [PMID: 28407327 DOI: 10.1002/jso.24626] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
339 Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012;122:4118-4129. [PMID: 23023703 DOI: 10.1172/jci63606] [Cited by in Crossref: 119] [Cited by in F6Publishing: 79] [Article Influence: 13.2] [Reference Citation Analysis]
340 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
341 Kotopoulis S, Stigen E, Popa M, Safont MM, Healey A, Kvåle S, Sontum P, Gjertsen BT, Gilja OH, McCormack E. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. J Control Release 2017;245:70-80. [PMID: 27871988 DOI: 10.1016/j.jconrel.2016.11.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
342 Saini F, Argent RH, Grabowska AM. Sonic Hedgehog Ligand: A Role in Formation of a Mesenchymal Niche in Human Pancreatic Ductal Adenocarcinoma. Cells 2019;8:E424. [PMID: 31072042 DOI: 10.3390/cells8050424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
343 Rizwani W, Allen AE, Trevino JG. Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge. Cancers (Basel) 2015;7:1785-805. [PMID: 26404380 DOI: 10.3390/cancers7030861] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
344 Huang MH, Chou YW, Li MH, Shih TE, Lin SZ, Chuang HM, Chiou TW, Su HL, Harn HJ. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition. Pharmacol Res 2019;139:50-61. [PMID: 30385365 DOI: 10.1016/j.phrs.2018.10.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
345 Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth. Oncotarget 2013;4:1632-46. [PMID: 24142503 DOI: 10.18632/oncotarget.1365] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
346 Yu Q, Qiu Y, Chen X, Wang X, Mei L, Wu H, Liu K, Liu Y, Li M, Zhang Z, He Q. Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex. Theranostics 2019;9:355-68. [PMID: 30809279 DOI: 10.7150/thno.29137] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
347 Byrne JD, Jajja MR, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2016;113:2200-5. [PMID: 26858448 DOI: 10.1073/pnas.1600421113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
348 Nielsen N, Lindemann O, Schwab A. TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration. Br J Pharmacol 2014;171:5524-40. [PMID: 24724725 DOI: 10.1111/bph.12721] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
349 Camus M, Vienne A, Mestas J, Pratico C, Nicco C, Chereau C, Marie J, Moussatov A, Renault G, Batteux F, Lafon C, Prat F. Cavitation-induced release of liposomal chemotherapy in orthotopic murine pancreatic cancer models: A feasibility study. Clinics and Research in Hepatology and Gastroenterology 2019;43:669-81. [DOI: 10.1016/j.clinre.2019.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
350 Concia M, Sprinkart AM, Penner AH, Brossart P, Gieseke J, Schild HH, Willinek WA, Mürtz P. Diffusion-weighted magnetic resonance imaging of the pancreas: diagnostic benefit from an intravoxel incoherent motion model-based 3 b-value analysis. Invest Radiol. 2014;49:93-100. [PMID: 24089021 DOI: 10.1097/rli.0b013e3182a71cc3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
351 McCarroll JA, Naim S, Sharbeen G, Russia N, Lee J, Kavallaris M, Goldstein D, Phillips PA. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol 2014;5:141. [PMID: 24782785 DOI: 10.3389/fphys.2014.00141] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
352 Andersen LMK, Wegner CS, Simonsen TG, Huang R, Gaustad JV, Hauge A, Galappathi K, Rofstad EK. Lymph node metastasis and the physicochemical micro-environment of pancreatic ductal adenocarcinoma xenografts. Oncotarget 2017;8:48060-74. [PMID: 28624797 DOI: 10.18632/oncotarget.18231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
353 Steer A, Cordes N, Jendrossek V, Klein D. Impact of Cancer-Associated Fibroblast on the Radiation-Response of Solid Xenograft Tumors. Front Mol Biosci 2019;6:70. [PMID: 31475157 DOI: 10.3389/fmolb.2019.00070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
354 Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53. [PMID: 22226241 DOI: 10.1016/j.ctrv.2011.12.004] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 8.1] [Reference Citation Analysis]
355 Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int. 2014;13:371-380. [PMID: 25100121 DOI: 10.1016/s1499-3872(14)60259-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
356 Fokas E, O’Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochim Biophys Acta. 2015;1855:61-82. [PMID: 25489989 DOI: 10.1016/j.bbcan.2014.12.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
357 Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM, Kocher HM. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. J Pathol 2016;239:286-96. [PMID: 27061193 DOI: 10.1002/path.4727] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 9.8] [Reference Citation Analysis]
358 Ma Y, Ullrich SE. Intratumoral mast cells promote the growth of pancreatic cancer. Oncoimmunology 2013;2:e25964. [PMID: 24353907 DOI: 10.4161/onci.25964] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
359 Lai SW, Bamodu OA, Chen JH, Wu AT, Lee WH, Chao TY, Yeh CT. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. Cells 2020;9:E911. [PMID: 32276472 DOI: 10.3390/cells9040911] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
360 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
361 Barraud M, Garnier J, Loncle C, Gayet O, Lequeue C, Vasseur S, Bian B, Duconseil P, Gilabert M, Bigonnet M, Maignan A, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Guibert N, Iovanna J, Dusetti N. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Oncotarget 2016;7:53783-96. [PMID: 27462772 DOI: 10.18632/oncotarget.10776] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
362 Ropolo A, Bagnes CI, Molejon MI, Lo Re A, Boggio V, Gonzalez CD, Vaccaro MI. Chemotherapy and autophagy-mediated cell death in pancreatic cancer cells. Pancreatology 2012;12:1-7. [PMID: 22487466 DOI: 10.1016/j.pan.2011.11.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
363 Panwar N, Yang C, Yin F, Yoon HS, Chuan TS, Yong KT. RNAi-based therapeutic nanostrategy: IL-8 gene silencing in pancreatic cancer cells using gold nanorods delivery vehicles. Nanotechnology 2015;26:365101. [PMID: 26291710 DOI: 10.1088/0957-4484/26/36/365101] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
364 Sereti E, Karagianellou T, Kotsoni I, Magouliotis D, Kamposioras K, Ulukaya E, Sakellaridis N, Zacharoulis D, Dimas K. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer? J Proteomics 2018;188:107-18. [PMID: 29398619 DOI: 10.1016/j.jprot.2018.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
365 Dhani NC, Serra S, Pintilie M, Schwock J, Xu J, Gallinger S, Hill RP, Hedley DW. Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. Br J Cancer 2015;113:864-71. [PMID: 26325106 DOI: 10.1038/bjc.2015.284] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
366 Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Anderson JM, Johansen JS, Hollingsworth MA, Yeh JJ, Collisson EA. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol 2018;2018. [PMID: 30506016 DOI: 10.1200/PO.17.00121] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
367 Obaid G, Bano S, Mallidi S, Broekgaarden M, Kuriakose J, Silber Z, Bulin AL, Wang Y, Mai Z, Jin W, Simeone D, Hasan T. Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia? Nano Lett 2019;19:7573-87. [PMID: 31518145 DOI: 10.1021/acs.nanolett.9b00859] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
368 Giri B, Sethi V, Modi S, Garg B, Banerjee S, Saluja A, Dudeja V. "Heat shock protein 70 in pancreatic diseases: Friend or foe". J Surg Oncol 2017;116:114-22. [PMID: 28543919 DOI: 10.1002/jso.24653] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
369 Neesse A, Griesmann H, Gress TM, Michl P. Claudin-4 as therapeutic target in cancer. Arch Biochem Biophys. 2012;524:64-70. [PMID: 22286027 DOI: 10.1016/j.abb.2012.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
370 Saluja AK, Dudeja V, Banerjee S. Evolution of novel therapeutic options for pancreatic cancer. Curr Opin Gastroenterol 2016;32:401-7. [PMID: 27454027 DOI: 10.1097/MOG.0000000000000298] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
371 Yokoi K, Godin B, Oborn CJ, Alexander JF, Liu X, Fidler IJ, Ferrari M. Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Lett 2013;334:319-27. [PMID: 23000514 DOI: 10.1016/j.canlet.2012.09.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
372 Hale MD, Hayden JD, Grabsch HI. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cell Oncol (Dordr) 2013;36:95-112. [PMID: 23494412 DOI: 10.1007/s13402-013-0127-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
373 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
374 Sleightholm R, Yang B, Yu F, Xie Y, Oupický D. Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy. Biomacromolecules 2017;18:2247-57. [PMID: 28708385 DOI: 10.1021/acs.biomac.7b00023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
375 Yamanaka K, Chatterjee N, Hemann MT, Walker GC. Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? PLoS Genet 2017;13:e1006842. [PMID: 28817566 DOI: 10.1371/journal.pgen.1006842] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
376 Garajová I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int. 2014;2014:678401. [PMID: 25250326 DOI: 10.1155/2014/678401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
377 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov 2015;5:1040-8. [PMID: 26109333 DOI: 10.1158/2159-8290.CD-15-0274] [Cited by in Crossref: 144] [Cited by in F6Publishing: 87] [Article Influence: 20.6] [Reference Citation Analysis]
378 Kumar AA, Buckley BJ, Ranson M. The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets. Biomolecules 2022;12:152. [DOI: 10.3390/biom12020152] [Reference Citation Analysis]
379 Mahmood J, Shukla HD, Soman S, Samanta S, Singh P, Kamlapurkar S, Saeed A, Amin NP, Vujaskovic Z. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers (Basel). 2018;10. [PMID: 30486519 DOI: 10.3390/cancers10120469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
380 Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol. 2012;3:270. [PMID: 22969725 DOI: 10.3389/fphys.2012.00270] [Cited by in Crossref: 11] [Cited by in F6Publishing: 40] [Article Influence: 1.1] [Reference Citation Analysis]
381 Lesinski GB. Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells. Ann Pancreat Cancer 2018;1:29. [PMID: 32542235 DOI: 10.21037/apc.2018.09.03] [Reference Citation Analysis]
382 Topalovski M, Brekken RA. Matrix control of pancreatic cancer: New insights into fibronectin signaling. Cancer Lett 2016;381:252-8. [PMID: 26742464 DOI: 10.1016/j.canlet.2015.12.027] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
383 Jiang JH, Liu C, Cheng H, Lu Y, Qin Y, Xu YF, Xu J, Long J, Liu L, Ni QX. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochim Biophys Acta. 2015;1855:43-49. [PMID: 25432020 DOI: 10.1016/j.bbcan.2014.11.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
384 Molejon MI, Tellechea JI, Loncle C, Gayet O, Gilabert M, Duconseil P, Lopez-Millan MB, Moutardier V, Gasmi M, Garcia S, Turrini O, Ouaissi M, Poizat F, Dusetti N, Iovanna J. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Oncotarget 2015;6:7408-23. [PMID: 25797268 DOI: 10.18632/oncotarget.3510] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
385 Geleta B, Park KC, Jansson PJ, Sahni S, Maleki S, Xu Z, Murakami T, Pajic M, Apte MV, Richardson DR, Kovacevic Z. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. FASEB J 2021;35:e21347. [PMID: 33484481 DOI: 10.1096/fj.202002279R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
386 Buchholz M, Honstein T, Kirchhoff S, Kreider R, Schmidt H, Sipos B, Gress TM. A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer. PLoS One 2015;10:e0122946. [PMID: 25849100 DOI: 10.1371/journal.pone.0122946] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
387 Lin H, Hu C, Zheng S, Zhang X, Chen R, Zhou Q. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Aging (Albany NY) 2021;13:12493-513. [PMID: 33901011 DOI: 10.18632/aging.202922] [Reference Citation Analysis]
388 Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB (Oxford) 2015;17:292-8. [PMID: 25250696 DOI: 10.1111/hpb.12334] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
389 Biffi G, Öhlund D, Tuveson D. Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma. Cell Death Differ 2016;23:1265-6. [PMID: 27285108 DOI: 10.1038/cdd.2016.50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
390 Bradney MJ, Venis SM, Yang Y, Konieczny SF, Han B. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. Small 2020;16:e1905500. [PMID: 31997571 DOI: 10.1002/smll.201905500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
391 Nielsen MFB, Mortensen MB, Detlefsen S. Identification of markers for quiescent pancreatic stellate cells in the normal human pancreas. Histochem Cell Biol. 2017;148:359-380. [PMID: 28540429 DOI: 10.1007/s00418-017-1581-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
392 Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 2019;19:307-25. [PMID: 31092904 DOI: 10.1038/s41568-019-0144-6] [Cited by in Crossref: 242] [Cited by in F6Publishing: 253] [Article Influence: 80.7] [Reference Citation Analysis]
393 Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C. Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell 2016;165:910-20. [PMID: 27087446 DOI: 10.1016/j.cell.2016.03.029] [Cited by in Crossref: 154] [Cited by in F6Publishing: 137] [Article Influence: 25.7] [Reference Citation Analysis]
394 Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van Laarhoven HW, Metselaar JM, Kuppen PJK, Vahrmeijer AL, Östman A, Sier CFM, Prakash J. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Sci Adv 2019;5:eaax2770. [PMID: 31517053 DOI: 10.1126/sciadv.aax2770] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
395 Cheng CS, Tan HY, Wang N, Chen L, Meng Z, Chen Z, Feng Y. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clin Transl Med 2021;11:e467. [PMID: 34185423 DOI: 10.1002/ctm2.467] [Reference Citation Analysis]
396 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
397 Steele CW, Gill NAK, Jamieson NB, Carter CR. Targeting inflammation in pancreatic cancer: Clinical translation. World J Gastrointest Oncol 2016; 8(4): 380-388 [PMID: 27096033 DOI: 10.4251/wjgo.v8.i4.380] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
398 Matera R, Saif MW. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. Expert Opin Emerg Drugs 2017;22:223-33. [PMID: 28783977 DOI: 10.1080/14728214.2017.1362388] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
399 Perera RM, Bardeesy N. Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. Cancer Discov 2015;5:1247-61. [PMID: 26534901 DOI: 10.1158/2159-8290.CD-15-0671] [Cited by in Crossref: 116] [Cited by in F6Publishing: 62] [Article Influence: 16.6] [Reference Citation Analysis]
400 Guo J, Xie K, Zheng S. Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer. Int J Biol Sci 2016;12:292-301. [PMID: 26929736 DOI: 10.7150/ijbs.14995] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
401 Amrutkar M, Vethe NT, Verbeke CS, Aasrum M, Finstadsveen AV, Sántha P, Gladhaug IP. Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. Cancers (Basel) 2020;12:E3628. [PMID: 33287390 DOI: 10.3390/cancers12123628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
402 Buckway B, Wang Y, Ray A, Ghandehari H. Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors. Int J Pharm 2013;456:202-11. [PMID: 23933441 DOI: 10.1016/j.ijpharm.2013.07.067] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
403 Pan S, Brentnall TA, Kelly K, Chen R. Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. Proteomics. 2013;13:710-721. [PMID: 23125171 DOI: 10.1002/pmic.201200319] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
404 Funel N, Giovannetti E, Pollina LE, del Chiaro M, Mosca F, Boggi U, Campani D. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Expert Review of Molecular Diagnostics 2014;11:695-701. [DOI: 10.1586/erm.11.62] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
405 Ulmasov B, Neuschwander-Tetri BA, Lai J, Monastyrskiy V, Trisha Bhat, Yates MP, Oliva J, Prinsen MJ, Ruminski PG, Griggs DW. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice. Cell Mol Gastroenterol Hepatol. 2016;2:499-518. [PMID: 28174730 DOI: 10.1016/j.jcmgh.2016.03.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
406 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
407 Sun L, Hu L, Cogdell D, Lu L, Gao C, Tian W, Zhang Z, Kang Y, Fleming JB, Zhang W. MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway. Autophagy 2017;13:703-14. [PMID: 28121485 DOI: 10.1080/15548627.2017.1280217] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
408 Ji T, Lang J, Wang J, Cai R, Zhang Y, Qi F, Zhang L, Zhao X, Wu W, Hao J, Qin Z, Zhao Y, Nie G. Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy. ACS Nano 2017;11:8668-78. [PMID: 28806504 DOI: 10.1021/acsnano.7b01026] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 19.4] [Reference Citation Analysis]
409 Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656-670. [PMID: 22541435 DOI: 10.1016/j.cell.2012.01.058] [Cited by in Crossref: 1062] [Cited by in F6Publishing: 987] [Article Influence: 106.2] [Reference Citation Analysis]
410 Subrahmanyam N, Ghandehari H. Harnessing Extracellular Matrix Biology for Tumor Drug Delivery. J Pers Med 2021;11:88. [PMID: 33572559 DOI: 10.3390/jpm11020088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
411 Usai A, Di Franco G, Piccardi M, Cateni P, Pollina LE, Vivaldi C, Vasile E, Funel N, Palmeri M, Dente L, Falcone A, Giunchi D, Massolo A, Raffa V, Morelli L. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Cancers (Basel) 2021;13:4131. [PMID: 34439284 DOI: 10.3390/cancers13164131] [Reference Citation Analysis]
412 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
413 Allen SD, Liu X, Jiang J, Liao YP, Chang CH, Nel AE, Meng H. Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor. Biomaterials 2021;269:120635. [PMID: 33422940 DOI: 10.1016/j.biomaterials.2020.120635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
414 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med 2012;60:643-63. [PMID: 22406516 DOI: 10.2310/JIM.0b013e31824a4d79] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
415 Lim JH, Park JS, Yoon DS. Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer. HPB 2017;19:388-95. [DOI: 10.1016/j.hpb.2016.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
416 Yee NS. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. Adv Exp Med Biol 2013;779:91-143. [PMID: 23288637 DOI: 10.1007/978-1-4614-6176-0_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
417 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435-444. [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 13.9] [Reference Citation Analysis]
418 Holbrook MC, Goad DW, Grdzelishvili VZ. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions. Cancers (Basel) 2021;13:1171. [PMID: 33803211 DOI: 10.3390/cancers13051171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
419 Garajová I, Le Large TY, Giovannetti E, Kazemier G, Biasco G, Peters GJ. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. Methods Mol Biol 2016;1395:163-87. [PMID: 26910074 DOI: 10.1007/978-1-4939-3347-1_10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
420 Sancho P, Alcala S, Usachov V, Hermann PC, Sainz B Jr. The ever-changing landscape of pancreatic cancer stem cells. Pancreatology. 2016;16:489-496. [PMID: 27161173 DOI: 10.1016/j.pan.2016.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
421 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
422 Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106:508-516. [PMID: 22187035 DOI: 10.1038/bjc.2011.545] [Cited by in Crossref: 164] [Cited by in F6Publishing: 164] [Article Influence: 14.9] [Reference Citation Analysis]
423 Dauer P, Zhao X, Gupta VK, Sharma N, Kesh K, Gnamlin P, Dudeja V, Vickers SM, Banerjee S, Saluja A. Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Cancer Res 2018;78:1321-33. [PMID: 29259015 DOI: 10.1158/0008-5472.CAN-17-2320] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
424 Grbovic-Huezo O, Pitter KL, Lecomte N, Saglimbeni J, Askan G, Holm M, Melchor JP, Chandwani R, Joshi S, Haglund C, Iacobuzio-Donahue CA, Chiosis G, Tammela T, Leach SD. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2020;117:30670-8. [PMID: 33199632 DOI: 10.1073/pnas.1920240117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
425 Keleg S, Titov A, Heller A, Giese T, Tjaden C, Ahmad SS, Gaida MM, Bauer AS, Werner J, Giese NA. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors. PLoS One 2014;9:e100178. [PMID: 24932730 DOI: 10.1371/journal.pone.0100178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
426 Handra-Luca A, Hammel P, Sauvanet A, Ruszniewski P, Couvelard A. Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas. J Hepatobiliary Pancreat Sci 2013;20:294-302. [PMID: 22581056 DOI: 10.1007/s00534-012-0518-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
427 Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 2015;75:2800-10. [PMID: 25979873 DOI: 10.1158/0008-5472.CAN-14-3041] [Cited by in Crossref: 208] [Cited by in F6Publishing: 143] [Article Influence: 29.7] [Reference Citation Analysis]
428 Tewari M. Pancreatic Cancer: a Challenge to Cure. Indian J Surg 2015;77:350-7. [PMID: 26722196 DOI: 10.1007/s12262-015-1369-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
429 Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013;144:1230-1240. [PMID: 23622132 DOI: 10.1053/j.gastro.2012.12.042] [Cited by in Crossref: 166] [Cited by in F6Publishing: 169] [Article Influence: 18.4] [Reference Citation Analysis]
430 Chen W, Yuan Y, Jiang X. Antibody and antibody fragments for cancer immunotherapy. J Control Release 2020;328:395-406. [PMID: 32853733 DOI: 10.1016/j.jconrel.2020.08.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
431 Banerjee S, Modi S, McGinn O, Zhao X, Dudeja V, Ramakrishnan S, Saluja AK. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. Clin Cancer Res 2016;22:415-25. [PMID: 26405195 DOI: 10.1158/1078-0432.CCR-15-1155] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
432 Katoh D, Kozuka Y, Noro A, Ogawa T, Imanaka-Yoshida K, Yoshida T. Tenascin-C Induces Phenotypic Changes in Fibroblasts to Myofibroblasts with High Contractility through the Integrin αvβ1/Transforming Growth Factor β/SMAD Signaling Axis in Human Breast Cancer. Am J Pathol 2020;190:2123-35. [PMID: 32650003 DOI: 10.1016/j.ajpath.2020.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
433 Matsubayashi H, Matsunaga K, Uesaka K, Kanemoto H, Ito I, Asakura H, Yagishita A, Ono H. Pancreatic adenosquamous carcinoma with 7-year survival: a case report and literature review. J Dig Dis. 2013;14:207-210. [PMID: 23176255 DOI: 10.1111/1751-2980.12018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
434 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
435 Yan Z, Ohuchida K, Fei S, Zheng B, Guan W, Feng H, Kibe S, Ando Y, Koikawa K, Abe T, Iwamoto C, Shindo K, Moriyama T, Nakata K, Miyasaka Y, Ohtsuka T, Mizumoto K, Hashizume M, Nakamura M. Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. J Exp Clin Cancer Res 2019;38:221. [PMID: 31133044 DOI: 10.1186/s13046-019-1226-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
436 Li W, Zhang Z, Nicolai J, Yang GY, Omary RA, Larson AC. Magnetization transfer MRI in pancreatic cancer xenograft models. Magn Reson Med 2012;68:1291-7. [PMID: 22213176 DOI: 10.1002/mrm.24127] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
437 Hernández-Camarero P, Jiménez G, López-Ruiz E, Barungi S, Marchal JA, Perán M. Revisiting the dynamic cancer stem cell model: Importance of tumour edges. Crit Rev Oncol Hematol 2018;131:35-45. [PMID: 30293704 DOI: 10.1016/j.critrevonc.2018.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
438 Chen Z, Zheng Y, Shi Y, Cui Z. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. Int J Nanomedicine 2018;13:319-36. [PMID: 29391792 DOI: 10.2147/IJN.S149196] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
439 Tchou J, Conejo-garcia J. Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer. Current Challenges in Personalized Cancer Medicine. Elsevier; 2012. pp. 45-61. [DOI: 10.1016/b978-0-12-397927-8.00003-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
440 Preda L, Conte G, Bonello L, Giannitto C, Travaini LL, Raimondi S, Summers PE, Mohssen A, Alterio D, Cossu Rocca M. Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma. Eur Radiol. 2016;. [PMID: 26965504 DOI: 10.1007/s00330-016-4284-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
441 Knudsen ES, Balaji U, Freinkman E, McCue P, Witkiewicz AK. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget 2016;7:78396-411. [PMID: 27623078 DOI: 10.18632/oncotarget.11893] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
442 DeCant BT, Principe DR, Guerra C, Pasca di Magliano M, Grippo PJ. Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. Front Physiol 2014;5:464. [PMID: 25538623 DOI: 10.3389/fphys.2014.00464] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
443 Truong LH, Pauklin S. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Cancers (Basel) 2021;13:5028. [PMID: 34638513 DOI: 10.3390/cancers13195028] [Reference Citation Analysis]
444 Pape J, Stamati K, Al Hosni R, Uchegbu IF, Schatzlein AG, Loizidou M, Emberton M, Cheema U. Tissue-Engineering the Fibrous Pancreatic Tumour Stroma Capsule in 3D Tumouroids to Demonstrate Paclitaxel Response. Int J Mol Sci 2021;22:4289. [PMID: 33924238 DOI: 10.3390/ijms22084289] [Reference Citation Analysis]
445 Brandes F, Schmidt K, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, Lang SA. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. BMC Cancer. 2015;15:71. [PMID: 25884642 DOI: 10.1186/s12885-015-1064-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
446 Benesova L, Halkova T, Bunganic B, Belsanova B, Zavoral M, Traboulsi E, Minarik M. Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer. Pathol Oncol Res. 2018;. [PMID: 30361898 DOI: 10.1007/s12253-018-0490-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
447 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
448 Secq V, Leca J, Bressy C, Guillaumond F, Skrobuk P, Nigri J, Lac S, Lavaut MN, Bui TT, Thakur AK, Callizot N, Steinschneider R, Berthezene P, Dusetti N, Ouaissi M, Moutardier V, Calvo E, Bousquet C, Garcia S, Bidaut G, Vasseur S, Iovanna JL, Tomasini R. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Cell Death Dis 2015;6:e1592. [PMID: 25590802 DOI: 10.1038/cddis.2014.557] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
449 Rodriguez-Aznar E, Wiesmüller L, Sainz B Jr, Hermann PC. EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells. Cancers (Basel) 2019;11:E1136. [PMID: 31398893 DOI: 10.3390/cancers11081136] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 10.7] [Reference Citation Analysis]
450 Li Y, Hong J, Oh JE, Yoon AR, Yun CO. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer. Int J Cancer 2018;142:392-413. [PMID: 28929492 DOI: 10.1002/ijc.31060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
451 Tjomsland V, Pomianowska E, Aasrum M, Sandnes D, Verbeke CS, Gladhaug IP. Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells. Neoplasia 2016;18:447-56. [PMID: 27435927 DOI: 10.1016/j.neo.2016.06.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
452 Adamo P, Cowley CM, Neal CP, Mistry V, Page K, Dennison AR, Isherwood J, Hastings R, Luo J, Moore DA, Howard PJ, Miguel ML, Pritchard C, Manson M, Shaw JA. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget 2017;8:87221-33. [PMID: 29152076 DOI: 10.18632/oncotarget.20250] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
453 Lei J, Huo X, Duan W, Xu Q, Li R, Ma J, Li X, Han L, Li W, Sun H, Wu E, Ma Q. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Cancer Lett 2014;347:129-38. [PMID: 24513179 DOI: 10.1016/j.canlet.2014.02.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
454 Moir JA, Mann J, White SA. The role of pancreatic stellate cells in pancreatic cancer. Surg Oncol 2015;24:232-8. [PMID: 26080604 DOI: 10.1016/j.suronc.2015.05.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
455 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
456 Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøtt J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release 2016;243:172-81. [PMID: 27744037 DOI: 10.1016/j.jconrel.2016.10.007] [Cited by in Crossref: 191] [Cited by in F6Publishing: 184] [Article Influence: 31.8] [Reference Citation Analysis]
457 Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014;8:1905-1918. [PMID: 25242334 DOI: 10.1016/j.celrep.2014.08.029] [Cited by in Crossref: 292] [Cited by in F6Publishing: 272] [Article Influence: 36.5] [Reference Citation Analysis]
458 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
459 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
460 Suzuki Y, Takadate T, Mizuma M, Shima H, Suzuki T, Tachibana T, Shimura M, Hata T, Iseki M, Kawaguchi K, Aoki T, Hayashi H, Morikawa T, Nakagawa K, Motoi F, Naitoh T, Igarashi K, Unno M. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. PLoS One 2020;15:e0235904. [PMID: 32663208 DOI: 10.1371/journal.pone.0235904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
461 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
462 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266-4276. [PMID: 22896693 DOI: 10.1158/1078-0432.ccr-11-3114] [Cited by in Crossref: 711] [Cited by in F6Publishing: 486] [Article Influence: 79.0] [Reference Citation Analysis]
463 Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554. [PMID: 21969517 DOI: 10.1200/jco.2011.36.5742] [Cited by in Crossref: 692] [Cited by in F6Publishing: 389] [Article Influence: 62.9] [Reference Citation Analysis]
464 Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 2014;5:78-94. [PMID: 24393789 DOI: 10.18632/oncotarget.1569] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 10.0] [Reference Citation Analysis]
465 Vincent P, Bruza P, Palisoul SM, Gunn JR, Samkoe KS, Hoopes PJ, Hasan T, Pogue BW. Visualization and quantification of pancreatic tumor stroma in fresh tissue via ultraviolet surface excitation. J Biomed Opt 2021;26. [PMID: 33423407 DOI: 10.1117/1.JBO.26.1.016002] [Reference Citation Analysis]
466 Vernucci E, Abrego J, Gunda V, Shukla SK, Dasgupta A, Rai V, Chaika N, Buettner K, Illies A, Yu F, Lazenby AJ, Swanson BJ, Singh PK. Metabolic Alterations in Pancreatic Cancer Progression. Cancers (Basel) 2019;12:E2. [PMID: 31861288 DOI: 10.3390/cancers12010002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
467 Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials 2016;93:71-82. [PMID: 27082874 DOI: 10.1016/j.biomaterials.2016.03.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
468 Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013;110:12325-12330. [PMID: 23836645 DOI: 10.1073/pnas.1300415110] [Cited by in Crossref: 152] [Cited by in F6Publishing: 182] [Article Influence: 16.9] [Reference Citation Analysis]
469 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine 2014;211:1503-23. [DOI: 10.1084/jem.20140692] [Reference Citation Analysis]
470 Yang Y, Shi XQ, Chen G, Zhou XN, Qian LX. Contrast-enhanced ultrasound for evaluating response to pulsed-wave high-intensity focused ultrasound therapy in advanced pancreatic cancer. Clin Hemorheol Microcirc 2022. [PMID: 35001881 DOI: 10.3233/CH-211342] [Reference Citation Analysis]
471 Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, Zhang B, Mehla K, Brown RB, Caffrey T, Yu F, Johnson KR, Powers R, Hollingsworth MA, Singh PK. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci USA. 2012;109:13787-13792. [PMID: 22869720 DOI: 10.1073/pnas.1203339109] [Cited by in Crossref: 133] [Cited by in F6Publishing: 136] [Article Influence: 13.3] [Reference Citation Analysis]
472 Usova EV, Kopantseva MR, Kostina MB, Van'kovich AN, Egorov VI, Kopantsev EP. Expression of the ZEB2 gene in pancreatic stromal cells in pancreatic ductal adenocarcinoma, pancreatitis, and normal state. Dokl Biol Sci 2013;448:61-4. [PMID: 23479023 DOI: 10.1134/S001249661301016X] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
473 Sada M, Ohuchida K, Horioka K, Okumura T, Moriyama T, Miyasaka Y, Ohtsuka T, Mizumoto K, Oda Y, Nakamura M. Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Cancer Lett. 2016;372:210-218. [PMID: 26805763 DOI: 10.1016/j.canlet.2016.01.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
474 Wu C, Kraft P, Stolzenberg-Solomon R, Steplowski E, Brotzman M, Xu M, Mudgal P, Amundadottir L, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, Kooperberg C, Petersen GM, Zheng W, Albanes D, Boutron-Ruault MC, Buring JE, Canzian F, Cao G, Duell EJ, Elena JW, Gaziano JM, Giovannucci EL, Hallmans G, Hutchinson A, Hunter DJ, Jenab M, Jiang G, Khaw KT, LaCroix A, Li Z, Mendelsohn JB, Panico S, Patel AV, Qian ZR, Riboli E, Sesso H, Shen H, Shu XO, Tjonneland A, Tobias GS, Trichopoulos D, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Yu K, Zeleniuch-Jacquotte A, Chanock S, Hoover R, Hartge P, Fuchs CS, Lin D, Wolpin BM. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut 2014;63:152-60. [PMID: 23180869 DOI: 10.1136/gutjnl-2012-303477] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
475 Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 2014;110:275-84. [PMID: 25042700 DOI: 10.1002/jso.23633] [Cited by in Crossref: 78] [Cited by in F6Publishing: 88] [Article Influence: 9.8] [Reference Citation Analysis]
476 Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. Cancers (Basel). 2015;7:2443-2458. [PMID: 26690480 DOI: 10.3390/cancers7040902] [Cited by in Crossref: 374] [Cited by in F6Publishing: 362] [Article Influence: 53.4] [Reference Citation Analysis]
477 Schober M, Jesenofsky R, Faissner R, Weidenauer C, Hagmann W, Michl P, Heuchel RL, Haas SL, Löhr JM. Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel) 2014;6:2137-54. [PMID: 25337831 DOI: 10.3390/cancers6042137] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
478 Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc 2017;86:161-9. [PMID: 27889543 DOI: 10.1016/j.gie.2016.11.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
479 Hu H, Hang JJ, Han T, Zhuo M, Jiao F, Wang LW. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumour Biol. 2016;37:8657-8664. [PMID: 26738860 DOI: 10.1007/s13277-015-4741-z] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 12.8] [Reference Citation Analysis]
480 Tandon M, Coudriet GM, Criscimanna A, Socorro M, Eliliwi M, Singhi AD, Cruz-Monserrate Z, Bailey P, Lotze MT, Zeh H, Hu J, Goffin V, Gittes GK, Biankin AV, Esni F. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Cancer Res 2019;79:5316-27. [PMID: 31395607 DOI: 10.1158/0008-5472.CAN-18-3064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
481 Mardhian DF, Storm G, Bansal R, Prakash J. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J Control Release 2018;290:1-10. [PMID: 30287265 DOI: 10.1016/j.jconrel.2018.09.031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
482 Li KY, Yuan JL, Trafton D, Wang JX, Niu N, Yuan CH, Liu XB, Zheng L. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Chronic Dis Transl Med 2020;6:6-17. [PMID: 32226930 DOI: 10.1016/j.cdtm.2020.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
483 Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology. 2012;142:1079-1092. [PMID: 22406637 DOI: 10.1053/j.gastro.2012.03.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 115] [Article Influence: 12.0] [Reference Citation Analysis]
484 Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. Pancreatology. 2021;21:363-378. [PMID: 33451936 DOI: 10.1016/j.pan.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
485 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 10.9] [Reference Citation Analysis]
486 Kahlert C, Fiala M, Musso G, Halama N, Keim S, Mazzone M, Lasitschka F, Pecqueux M, Klupp F, Schmidt T, Rahbari N, Schölch S, Pilarsky C, Ulrich A, Schneider M, Weitz J, Koch M. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Oncotarget 2014;5:12978-89. [PMID: 25483099 DOI: 10.18632/oncotarget.2651] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
487 Lane LA. Physics in nanomedicine: Phenomena governing the in vivo performance of nanoparticles. Applied Physics Reviews 2020;7:011316. [DOI: 10.1063/1.5052455] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
488 Coleman SJ, Watt J, Arumugam P, Solaini L, Carapuca E, Ghallab M, Grose RP, Kocher HM. Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. World J Gastroenterol 2014; 20(26): 8471-8481 [PMID: 25024603 DOI: 10.3748/wjg.v20.i26.8471] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
489 Saha S, Xiong X, Chakraborty PK, Shameer K, Arvizo RR, Kudgus RA, Dwivedi SK, Hossen MN, Gillies EM, Robertson JD, Dudley JT, Urrutia RA, Postier RG, Bhattacharya R, Mukherjee P. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano 2016;10:10636-51. [PMID: 27758098 DOI: 10.1021/acsnano.6b02231] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 13.0] [Reference Citation Analysis]
490 Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witkiewicz AK. Pancreatic cancer cell lines as patient-derived avatars: Genetic characterisation and functional utility. Gut. 2018;67:508-520. [PMID: 28073890 DOI: 10.1136/gutjnl-2016-313133] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 10.4] [Reference Citation Analysis]
491 Pigula M, Huang HC, Mallidi S, Anbil S, Liu J, Mai Z, Hasan T. Size-dependent Tumor Response to Photodynamic Therapy and Irinotecan Monotherapies Revealed by Longitudinal Ultrasound Monitoring in an Orthotopic Pancreatic Cancer Model. Photochem Photobiol 2019;95:378-86. [PMID: 30229942 DOI: 10.1111/php.13016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]